Document:

Common Stock Purchase Agreement

 Exhibit 10.38 

 
 REGULUS THERAPEUTICS INC. 

COMMON STOCK PURCHASE AGREEMENT 
 August 14, 2012 

 REGULUS THERAPEUTICS INC. 

COMMON STOCK PURCHASE AGREEMENT 
 THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of
August 14, 2012, by and between REGULUS THERAPEUTICS INC., a Delaware corporation (the “Company”), and ASTRAZENECA AB, a limited
liability company organized under the laws of Sweden (“Purchaser”). 
 RECITALS

 WHEREAS, concurrent with the execution of this Agreement, the
Company and Purchaser have entered into that certain Collaboration and License Agreement, dated the date hereof (the “Collaboration and License Agreement”); 

WHEREAS, the Company has authorized the sale and issuance to Purchaser of its Common
Stock, par value $0.001 per share (“Common Stock”), with an aggregate purchase price of $25,000,000 (subject to adjustment pursuant to Section 1.1 below) (the “Shares”); 

WHEREAS, Purchaser desires to purchase the Shares on the terms and conditions set
forth herein; and 
 WHEREAS, the Company desires to issue and sell the
Shares to Purchaser on the terms and conditions set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 

	 	 1.
	 AGREEMENT TO SELL AND PURCHASE. 

1.1        Closing.    In the event that the Company
consummates an initial public offering of its Common Stock pursuant to an effective registration statement under the Securities 

  
 1. 

 
Act of 1933, as amended (the “Securities Act”), on or before March 31, 2013 pursuant to which the Company either receives aggregate gross proceeds from the public of
at least $50 million or pursuant to which all of the Company’s outstanding convertible preferred stock convert to Common Stock of the Company (a “Triggering IPO”), Purchaser agrees to purchase, subject to the terms and
conditions set forth in this Agreement, in a concurrent private placement exempt from the registration requirements of the Securities Act, an aggregate of $25 million (the “Committed Investment Amount”) of the Company’s
Common Stock at a price per share equal to the per share initial public offering price (the “Purchase Price”) in a closing to be held concurrently with the closing of the Triggering IPO (the
“Closing”); provided, however, that (i) to the extent such investment would result in Purchaser, together with its affiliates, beneficially owning in excess of 19.99% of the outstanding shares of Common Stock or the
voting power of the Company (the “Ownership Maximum”), then the number of shares of Common Stock purchased by Purchaser pursuant to this Agreement, together with the Committed Investment Amount, shall be reduced to the extent
necessary such that such beneficial ownership does not exceed the Ownership Maximum, and (ii) to the extent a person not a party to this Agreement is entitled to purchase shares of Common Stock of the Company on the Closing Date (as defined
below) at a price per share more favorable than the Purchase Price, then the Purchase Price shall be adjusted to the same price per share of such Common Stock sold to such third party. 

1.2        Closing Date.    The Closing, if any,
shall take place concurrently with the date and time set for the closing of the Triggering IPO at the offices of the Company, 3545 John Hopkins Court, San Diego, California 92121, or such other time or place as the Company and Purchaser may mutually
agree (the date of such closing is hereinafter referred to as the “Closing Date”). At the Closing, subject to the terms and conditions set forth in this Agreement and in consideration of the payment by Purchaser of the
aggregate purchase price for the Shares, the Company will deliver to Purchaser a certificate representing the Shares. If the Closing does not occur on the date of the closing of a Triggering IPO, then this Agreement and the Collaboration and License
Agreement shall automatically terminate effective as of the day immediately following the date of the closing of the Triggering IPO. For the avoidance of doubt, until such termination occurs, the Company and Purchaser will continue to be bound
by their respective obligations under the Collaboration and License Agreement. 

1.3        Investor Rights Agreement.    In
conjunction with the Closing, the parties shall enter into the Investor Rights Agreement, substantially in the form attached hereto as Exhibit A (the “Investor Rights Agreement”). 

  
 2. 

 1.4        Alternative Funding
Terms.    In the event that the Company either (a) does not close a Triggering IPO on or before March 31, 2013 or (b) delivers to Purchaser at any time prior to March 31, 2013 a written notice (the
“Notice”) of the Company’s determination that the closing of a Triggering IPO on or before March 31, 2013 would not be feasible due to the impact of market conditions or otherwise, then the parties shall use
reasonable efforts to negotiate and execute a written agreement with respect to an alternative structure by the earlier of (i) the date that is 90 days following Purchaser’s receipt of the Notice or (ii) April 30, 2013 (the
earlier to occur, the “Alternative Funding Execution Date”), pursuant to which Purchaser will provide the Committed Investment Amount to the Company (the “Alternative Funding”). The closing of the
Alternative Funding, if any, shall occur on or before June 30, 2013 (the “Alternative Funding Closing Deadline Date”). If (x) the obligation to negotiate and proceed with the closing of an Alternative Funding
has been triggered pursuant to the occurrence of an event described in clause (a) or (b) above and the parties have not executed a written agreement with respect to an Alternative Funding on or prior to the Alternative Funding Execution
Date, or (y) the parties execute a written agreement with respect to an Alternative Funding prior to the Alternative Funding Execution Date but the closing of the Alternative Funding (including receipt by the Company of the full Committed
Investment Amount from Purchaser) does not occur on or prior to the Alternative Funding Closing Deadline Date, then in the case of either (x) or (y) this Agreement and the Collaboration and License Agreement shall automatically terminate
effective as of, in the case of (x) the day immediately following the Alternative Funding Execution Date and in the case of (y) the day immediately following the Alternative Funding Closing Deadline Date. For the avoidance of doubt,
until such termination occurs, the Company and Purchaser will continue to be bound by their respective obligations under the Collaboration and License Agreement. 
  

	 	 2.
	 REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 Except as set forth on a Schedule of Exceptions delivered by the Company to Purchaser
on the date of this Agreement, and an update to such Schedule of Exceptions delivered by the Company at the Closing, the Company hereby represents and warrants to Purchaser as of the date of this Agreement and as of the date of Closing as set forth
below; provided, however, that the representations and warranties of the Company included herein shall be deemed to be updated and modified by information included in the registration statement relating to the Triggering IPO as of its
effective date, and any modification or amendment thereto prior to the Closing, a copy of which shall have been furnished to Purchaser prior to the Closing and on which Purchaser shall be entitled to rely. The Schedule of Exceptions shall be
arranged in 

  
 3. 

 
sections corresponding to the numbered and lettered sections and subsections contained in this Section 2, and the disclosures in any section or subsection of the Schedule of Exceptions shall
qualify other sections and subsections in this Section 2 only to the extent it is reasonably apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. 

2.1        Organization, Good Standing and
Qualification.    The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite corporate power and authority to own and operate its
properties and assets, to execute and deliver this Agreement, to issue and sell the Shares, and to carry out the provisions of this Agreement and to carry on its business as presently conducted. The Company is duly qualified to do business and is in
good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in which failure to do so would not
have a material adverse effect on the Company or its business. 

2.2        Subsidiaries.    The Company does not own
or control, directly or indirectly, any equity security or other interest of any other corporation, partnership, limited liability company, association, trust, joint venture or other business entity. The Company is not a participant in any joint
venture, partnership, limited liability company or similar arrangement. Since its inception, the Company has not consolidated or merged with, acquired all or substantially all of the assets of, or acquired the stock of or any interest in any
corporation, partnership, limited liability company, association, trust, joint venture or other business entity. 
 2.3        Capitalization; Voting Rights. 
 (a)        Section 2.3 of the Schedule of Exceptions sets forth (i) the number of authorized and outstanding shares of Common Stock and
(ii) the number of authorized and outstanding shares of each series of Preferred Stock, in each case as of the date of this Agreement (with an update to be provided prior to the Closing with such information as of immediately prior to the
Closing). 
 (b)        Section 2.3 of the Schedule of
Exceptions sets forth, in each case as of the date of this Agreement under the Company’s equity incentive plan (the “Plan”) (i) the number of shares that have been issued pursuant to restricted stock purchase
agreements and/or the exercise of outstanding options, (ii) the number of options to purchase shares that have been granted and are outstanding, and (iii) the number of shares of Common Stock that remain

  
 4. 

 
available for future issuance to officers, directors, employees and consultants of the Company (with an update to be provided prior to the Closing with such information as of immediately prior to
the Closing). Each outstanding Company stock option (i) has an exercise price at least equal to the fair market value of the underlying stock on a date no earlier than the date of the corporate action authorizing the grant, and (ii) all
outstanding Company stock options have been issued in material compliance with all applicable laws and properly accounted for in all material respects in accordance with United States generally accepted accounting principles. 

(c)        Section 2.3 of the Schedule of Exceptions sets forth the
capitalization of the Company as of the date of this Agreement including the number of shares of the following: (i) the authorized, issued and outstanding Common Stock; (ii) underlying issued and outstanding stock options;
(iii) reserved for future issuance under the Plan; (iv) issued and outstanding Preferred Stock; (v) reserved for future issuance upon conversion of issued and outstanding Preferred Stock; and (vi) underlying issued and
outstanding warrants or stock purchase rights, if any (with an update to be provided prior to the Closing with such information as of immediately prior to the Closing). Other than as set forth in Section 2.3 of the Schedule of Exceptions and
except as may be granted pursuant to this Agreement, there are no, and at the time of the Closing there will not be any, outstanding options, warrants, rights (including conversion or preemptive rights or rights of participation, first refusal or
similar rights), proxy, stockholder or investor rights agreements, or agreements of any kind, orally or in writing, for the purchase or acquisition from the Company of any of its securities. All applicable preemptive rights have been complied with
or properly waived with respect to all prior issuances of capital stock. 

(d)        All issued and outstanding shares of the Company’s voting
stock (i) have been duly authorized and validly issued and are fully paid and nonassessable, and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 

(e)        The consummation of the transactions contemplated hereunder
will not result in any anti-dilution adjustment or other similar adjustment to any outstanding shares of capital stock of the Company. When issued in compliance with the provisions of this Agreement, the Shares will be validly issued, fully paid and
nonassessable, and will be free of any liens, restrictions or other encumbrances other than (i) liens and encumbrances created by or imposed upon Purchaser, (ii) any right of first refusal set forth in the Company’s Bylaws and
(iii) restrictions set forth in this Agreement or the Company’s Amended and Restated Certificate of 

  
 5. 

 
Incorporation (the “Amended and Restated Charter”); provided, however, that the Shares may be subject to restrictions on transfer set forth in the Investor Rights
Agreement and under state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time a transfer is proposed. The sale of the Shares to Purchaser hereunder is not and will not be subject to any preemptive
rights or rights of first refusal that have not been properly waived or complied with. 

2.4        Authorization; Binding Obligations.    All
corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of this Agreement, the performance of all obligations of the Company hereunder and thereunder at the Closing and the authorization,
sale, issuance and delivery of the Shares pursuant hereto has been taken. This Agreement, when executed and delivered, will be a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the
availability of equitable remedies. 
 2.5        Financial
Statements.    The Company has made available to Purchaser (a) its audited balance sheet as at December 31, 2011 and audited statement of income and cash flows for the twelve months ended December 31, 2011, and
(b) its unaudited balance sheet as at June 30, 2012 (the “Statement Date”) and unaudited statement of income and cash flows for the six-month period ended on the Statement Date (collectively, the
“Financial Statements”). The Financial Statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a
consistent basis throughout the periods indicated, except as disclosed therein, and present fairly the financial condition and position of the Company as of December 31, 2011 and the Statement Date, respectively; provided,
however, that the unaudited financial statements are subject to normal recurring year-end audit adjustments (which are not expected to be material either individually or in the aggregate and which are consistent with the Company’s books
and records), and do not contain all footnotes required under GAAP. The books and records of the Company are true, correct and complete in all material respects. The Company maintains a system of internal accounting controls which are sufficient to
provide reasonable assurance that (w) transactions are executed in accordance with the Company’s signature authority policy; (x) transactions are recorded as necessary to permit preparation of the financial statements of the Company
and to maintain accountability for the Company’s assets; (y) access to the Company’s assets is permitted only in accordance with management’s authorization; and (z) the reporting of the Company’s assets is compared with

  
 6. 

 
existing assets at regular intervals. The Company undertakes to provide Purchaser, prior to the Closing, any audited financial statements or unaudited interim financial statements of the Company
prepared after the date of this Agreement, which shall thereafter be deemed Financial Statements for the purposes of this Agreement. 
 2.6        Independent Auditor.    Ernst & Young LLP, who have audited the Financial Statements (to the extent the Financial
Statements are audited), is an independent registered public accounting firm as required by Regulation S-X under the Securities Act and the Public Company Accounting Oversight Board (United States). 

2.7        Liabilities.    The Company has no
material liabilities and to the best of its knowledge no material contingent liabilities, in each case of the type required to be disclosed in the liabilities column of a balance sheet prepared in accordance with GAAP, that are not disclosed in the
Financial Statements, except current liabilities incurred in the ordinary course of business subsequent to the Statement Date that are not material, either in any individual case or in the aggregate. 

2.8        Obligations to Related Parties.    There
are no obligations of the Company to officers, directors, stockholders or employees of the Company other than (a) for payment of salary for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company,
(c) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company) and (d) pursuant to the
agreements set forth in Section 2.8 of the Schedule of Exceptions, and all such agreements and arrangements set forth in (a) through (d) are on commercially reasonable, arms’ length terms. None of the officers, directors or, to
the best of the Company’s knowledge, key employees or stockholders of the Company or any members of their immediate families, is indebted to the Company or has any direct or indirect ownership interest in any firm or corporation with which the
Company is affiliated or with which the Company has a business relationship, or any firm or corporation that competes with the Company, other than passive investments in publicly traded companies (representing less than one percent of such company)
which may compete with the Company. No officer, director or stockholder or, to the Company’s knowledge, any member of their immediate families is, directly or indirectly, interested in any material contract with the Company (other than such
contracts as relate to any such person’s ownership of capital stock or other securities of the Company). 

2.9        Changes.    Since the Statement Date,
there has not been any: 

  
 7. 

 (a)        resignation or
termination of any officer, employee, consultant or group of employees of the Company; 

(b)        material change in the contingent obligations of the Company
by way of guaranty, endorsement, indemnity, warranty or otherwise; 

(c)        damage, destruction or loss, whether or not covered by
insurance, in excess of $10,000 individually or $50,000 in the aggregate affecting the properties, business or prospects or financial condition of the Company; 

(d)        waiver by the Company of a valuable right or of a material
debt owed to it; 
 (e)        (i) material change in any
compensation arrangement or agreement with any employee, officer, director or stockholder of the Company, (ii) labor dispute, other than routine individual grievances, or any lockouts, strikes, slowdowns, work stoppages or threats thereof by or
with respect to the Company’s employees, (iii) new agreement or arrangement (written or oral) to pay, conditionally or otherwise, any bonus, incentive, retention or other compensation, retirement, welfare, fringe or severance benefit or
vacation pay, to or in respect of, any employee, officer, director or stockholder of the Company (whether current, former or retired), or (iv) entering into or adoption of any new, or any material increase in benefits under or renewal,
amendment or termination of any existing, employee benefit plan or arrangement or any collective bargaining agreement; 
 (f)        labor organization activity related to the Company or its employees; 

(g)        debt, obligation or liability incurred, assumed or guaranteed
by the Company, except those for immaterial amounts and for current liabilities incurred in the ordinary course of business; 
 (h)        sale, lease, assignment or exclusive license or transfer of any patents, trademarks, copyrights, trade secrets or other intangible assets;

 (i)        other event or condition of any character that,
either individually or cumulatively, has materially and adversely affected the business, assets, liabilities, financial condition, prospects or operations of the Company; or 

  
 8. 

 (j)        arrangement or
commitment by the Company to do any of the acts described in subsection (a) through (i) above. 

2.10        Title to Properties and Tangible Assets; Liens,
Etc.    The Company has good and marketable title to its properties and tangible assets and good title to its leasehold estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than
(a) those resulting from taxes which have not yet become delinquent, (b) minor liens and encumbrances which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company, and
(c) those that have otherwise arisen in the ordinary course of business. 

2.11        Data Privacy.    The Company maintains
policies and procedures regarding data security, privacy and data use that are commercially reasonable and, in any event, comply with the Company’s obligations under applicable laws, rules and regulations. To the knowledge of the Company, there
have not been, and the transaction contemplated under this Agreement will not result in, any security breaches of any security policy, data use restriction or privacy breach under any such policies or any applicable laws, rules or regulations. No
claims have been asserted or, to the knowledge of the Company, threatened against the Company by any person alleging a violation of such person’s privacy, personal or confidentiality rights under any applicable rules, policies or procedure.

 2.12        Intellectual Property. 

(a)        To the Company’s knowledge, the Company is the sole and
exclusive owner of, or has a valid and continuing right to use pursuant to written license agreements, or possesses sufficient legal rights to, all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and
other proprietary rights and processes necessary to operate the business of the Company as presently conducted (“Company Intellectual Property”), without any known infringement of the valid rights of others. There are no
outstanding options, licenses or agreements of any kind relating to the Company Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the Company Intellectual Property,
except, in each case, for standard end-user, object code, internal-use software license and support/maintenance agreements or other licenses or agreements arising from the purchase of “off the shelf” or standard products. 

(b)        The Company is not aware that any of its employees,
consultants or contractors is obligated under any contract (including licenses, covenants or commitments of 

  
 9. 

 
any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with their duties to the Company or that would conflict
with the Company’s business as presently conducted. The Company has taken all reasonable action to maintain and protect the secrecy and confidentiality of trade secrets, confidential or proprietary know-how, and other confidential or
proprietary information within the Company Intellectual Property, including, without limitation, requiring all employees, consultants, contractors and other persons with access to trade secrets or proprietary information of the Company to execute
binding confidentiality agreements with respect thereto and, to the knowledge of the Company, no such employee, consultant, contractor or other person is in breach of any such confidentiality agreement. The Company has secured from all employees,
consultants, contractors and other persons who have contributed to the creation or development of any Company Intellectual Property written assignments of all rights to such contributions. Each current and former employee and consultant of the
Company has executed a proprietary information and inventions agreement in the form(s) delivered to Purchaser. No employee or consultant of the Company has excluded works or inventions made prior to his or her employment with the Company from his or
her assignment of inventions pursuant to such employee or consultant’s proprietary information and inventions agreement that the Company believes it is or will be necessary to use, except for works or inventions that have been assigned or
licensed to the Company. 
 2.13        Compliance with Other
Instruments.    The Company is not in violation or default of any term of its charter documents, each as amended, or of any provision of any mortgage, indenture, contract, lease, license, agreement, instrument, permit,
purchase order or contract to which it is a party or by which it is bound or of any judgment, decree, order or writ other than any such violation that would not have a material adverse effect on the Company. The execution, delivery, and performance
of and compliance with this Agreement, and the issuance and sale of the Shares pursuant hereto will not, with or without the passage of time or giving of notice, result in any such violation, or be in conflict with or constitute a default under (or
require a consent under) any such term or provision, or result in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or the suspension, revocation, impairment, forfeiture or
nonrenewal of any permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties. 
 2.14        Litigation.    There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or, to
the Company’s knowledge, currently threatened 

  
 10.

 
in writing against the Company that would reasonably be expected to result, either individually or in the aggregate, in any material adverse change in the assets, condition, affairs or prospects
of the Company, financially or otherwise, or any change in the current equity ownership of the Company or that questions the validity of this Agreement or the right of the Company to enter into such agreement, or to consummate the transactions
contemplated hereby, nor is the Company aware that there is any basis for any of the foregoing. 

2.15        Tax Returns and Payments.    The Company
has timely filed all tax returns (federal, state, local and foreign) required to be filed by it and all such tax returns are correct and complete in all material respects. All taxes shown to be due and payable on such returns, any assessments
imposed and all other taxes due and payable by the Company on or before the Closing, have been timely paid or will be paid prior to the time they become delinquent. The Company has not been advised (a) that any of its returns, federal, state or
other, have been or are being audited or examined as of the date hereof or (b) of any deficiency in assessment or proposed judgment to the Company’s federal, state or other taxes. The Company has no knowledge of any liability of any tax to
be imposed upon its properties or assets as of the date of this Agreement that is not adequately provided for. 

2.16        Compliance with Laws; Permits.    To its
knowledge, the Company is not in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of
its properties, which violation would materially and adversely affect the business, assets, liabilities, financial condition or operations of the Company. No governmental orders, permissions, consents, approvals or authorizations are required to be
obtained and no registrations or declarations are required to be filed in connection with the execution and delivery of this Agreement or the issuance of the Shares, except such as have been duly and validly obtained or filed, or with respect to any
filings that must be made after the Closing, as will be filed in a timely manner. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business as now being conducted by it, the lack of which
could materially and adversely affect the business, assets, properties or financial condition of the Company and believes it can obtain, without undue burden or expense, any similar authority for the conduct of its business as planned to be
conducted. 
 2.17        Foreign Corrupt Practices
Act.    Neither the Company nor, to the Company’s knowledge, any employee or agent of the Company, has while acting on behalf of the Company (i) used any corporate funds for unlawful contributions, gifts,
entertainment or 

  
 11.

 
other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or
campaigns from corporate funds, (iii) violated any provision of the Foreign Corrupt Practices Act of 1977, as amended or (iv) made any other unlawful payment. 

2.18        OFAC.    Neither the Company nor, to the
Company’s knowledge, any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(“OFAC”); and the Company will not directly or indirectly use the proceeds from the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity, for
the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 
 2.19        Environmental and Safety Laws.    To its knowledge, the Company is not in violation of any applicable statute, law or
regulation relating to the environment or occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. 

2.20        Offering Valid.    Assuming the accuracy
of the representations and warranties of Purchaser contained in Section 3.2 hereof, the offer, sale and issuance of the Shares will be exempt from the registration requirements of the Securities Act and will have been registered or qualified
(or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. Neither the Company nor any agent on its behalf has taken any action to, nor has any plans to,
solicit any offers to sell or offer to sell or sell all or any part of the Shares to any person or persons so as to bring the sale of such Shares by the Company within the registration provisions of the Securities Act or any state securities laws.

 2.21        Use of Proceeds.    The
Company shall use the proceeds from the issuance and sale of the Shares solely for general corporate purposes arising in the ordinary course of business and for research and development, working capital and growth and to repay any reasonable
expenses incurred in connection with the consummation of the transactions contemplated by this Agreement. None of the proceeds from the issuance and sale of the Shares shall, directly or indirectly, otherwise be used to repay any outstanding
indebtedness or other liabilities of the Company, in the payment of any debt for borrowed money of the Company, to otherwise repurchase or cancel any outstanding debt or equity securities of the Company or to declare a dividend or distribution to
the stockholders of the Company. 

  
 12.

2.22        Listing.    Upon consummation of a
Triggering IPO, the Common Stock shall, at the time of the Closing, be listed on the NASDAQ Stock Market (“Nasdaq”). 
 2.23        No Brokers.    The Company is not a party to any contract, agreement or understanding with any person that would give rise to
a valid claim against the Company for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Shares or any transaction contemplated by this Agreement. 

2.24        Full Disclosure.    The Company has
provided to Purchaser all information, documents and agreements that are material to an investment in the Shares. None of this Agreement, the exhibits hereto, or any other document delivered by the Company to Purchaser or its attorneys or agents in
connection herewith or therewith or with the transactions contemplated hereby or thereby contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not
misleading. 
  

	 	 3.
	 REPRESENTATIONS AND WARRANTIES OF PURCHASER.

 Purchaser hereby represents and warrants to the Company as of the date of this
Agreement as follows (provided that such representations and warranties do not lessen or obviate the representations and warranties of the Company set forth in this Agreement): 

3.1        Requisite Power and
Authority.    Purchaser has all necessary power and authority to execute and deliver this Agreement and to carry out its provisions. All action on Purchaser’s part required for the lawful execution and delivery of this
Agreement has been taken. Upon its execution and delivery, this Agreement will be a valid and binding obligation of Purchaser, enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the availability of equitable remedies. 

3.2        Investment Representations.    Purchaser
understands that the Shares have not been registered under the Securities Act. Purchaser also understands that the Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon
Purchaser’s representations contained in this Agreement. Purchaser hereby represents and warrants as follows: 

  
 13.

 (a)        Purchaser Bears
Economic Risk.    Purchaser has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks
of its investment in the Company and has the capacity to protect its own interests. Purchaser must bear the economic risk of this investment indefinitely unless the Shares are registered pursuant to the Securities Act, or an exemption from
registration is available. Purchaser understands that the Company has no present intention of registering the Shares or any other securities issued in respect of the Shares upon any stock split, stock dividend, recapitalization, merger,
consolidation or similar event. Purchaser also understands that there is no assurance that any exemption from registration under the Securities Act will be available and that, even if available, such exemption may not allow Purchaser to transfer all
or any portion of the Shares under the circumstances, in the amounts or at the times Purchaser might propose. 

(b)        Acquisition for Own Account.    Purchaser
is acquiring the Shares for Purchaser’s own account for investment only, and not with a view towards their distribution. 
 (c)        Purchaser Can Protect Its Interest.    Purchaser represents that by reason of its, or of its management’s, business or
financial experience, Purchaser has the capacity to protect its own interests in connection with the transactions contemplated in this Agreement. Further, Purchaser is aware of no publication of any advertisement in connection with the transactions
contemplated in this Agreement. 
 (d)        Accredited
Investor.    Purchaser represents that it is an accredited investor within the meaning of Regulation D under the Securities Act. 
 (e)        Foreign Investors.    If Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal
Revenue Code of 1986, as amended) (a “Foreign Purchaser”), Purchaser has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement,
including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained,
and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Shares. Purchaser’s subscription and payment for and continued beneficial ownership of the
Shares, will not violate any applicable securities or other laws of Purchaser’s jurisdiction. 

  
 14.

 (f)        Company
Information.    Purchaser has received and read the Company’s financial statements and has had an opportunity to discuss the Company’s business, management and financial affairs with directors, officers and
management of the Company and has had the opportunity to review the Company’s operations and facilities. Purchaser has also had the opportunity to ask questions of and receive answers from, the Company and its management regarding the terms and
conditions of this investment. 
 (g)        Rule
144.    Purchaser acknowledges and agrees that the Shares are “restricted securities” as defined in Rule 144 promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless
they are subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser has been advised or is aware of the provisions of Rule 144, which permits limited resale of securities purchased in a private
placement subject to the satisfaction of certain conditions, including, among other things: the availability of certain current public information about the Company, the resale occurring following the required holding period under Rule 144 and the
number of securities being sold during any three-month period not exceeding specified limitations. 

(h)        Residence.    The office or offices of
Purchaser in which its investment decision was made is located at the address or addresses of Purchaser set forth on the signature page hereof. 
 3.3        Transfer Restrictions.    Purchaser acknowledges and agrees that the Shares are subject to restrictions on transfer as set
forth in the Investor Rights Agreement. 

3.4        Legends.    Purchaser understands and
agrees that the certificates evidencing the Shares, or any other securities issued in respect of the Shares upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall bear the legends required by this
Agreement and the Investor Rights Agreement, including legends relating to restrictions on transfer under federal and state securities laws and legends required under applicable state securities laws. 

 

	 	 4.
	 CONDITIONS TO CLOSING. 

4.1        Conditions to Purchaser’s Obligations at the
Closing.    Purchaser’s obligations to purchase the Shares at the Closing are subject to the satisfaction (or waiver by Purchaser), at or prior to the Closing Date, of the following conditions: 

  
 15.

 (a)        Representations and
Warranties True; Performance of Obligations.    The representations and warranties made by the Company in Section 2 hereof shall be true and correct in all material respects as of the Closing Date, except in each case,
for those representations and warranties that address matters only as of a particular date, which shall be true and correct in all material respects as of such date, and the Company shall have performed all obligations and conditions herein required
to be performed or observed by it at or prior to the Closing. 

(b)        Investor Rights Agreement.    The Company
and each other party thereto (other than Purchaser) shall have executed and delivered the Investor Rights Agreement. 
 (c)        Stockholder Approval.    The Company shall have procured the necessary stockholder approval to the extent required under the
Delaware General Corporation Law, the California Corporations Code, the Amended and Restated Charter, and any voting or other agreement among the stockholders and the Company for the approval of the transactions contemplated by this Agreement,
including any amendment of the Amended and Restated Charter. 

(d)        Legal Investment.    On the Closing Date,
the sale and issuance of the Shares shall be legally permitted by all laws and regulations to which Purchaser and the Company are subject. 
 (e)        Legal Opinion.    The Purchaser shall have received an opinion from counsel to the Company, dated as of the Closing Date,
substantially in the form attached hereto as Exhibit B. 

(f)        Consents, Permits, and Waivers.    The
Company shall have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement (including any filing required to comply with the Hart Scott Rodino Antitrust
Improvements Act of 1976) except for such as may be properly obtained subsequent to the Closing. 

(g)        Share Certificates.    The Company shall
have executed a stock certificate in favor of Purchaser representing the Shares purchased at the Closing. 

(h)        Compliance Certificate.    The Company
shall have delivered to Purchaser a Compliance Certificate, executed by the President of the Company, dated as of the 

  
 16.

 
Closing Date, to the effect that the conditions specified in subsections (a) and (c) of this Section 4.1 have been satisfied. 

(i)        Secretary’s Certificate.    At the
Closing, Purchaser shall have received from the Company’s Secretary a certificate having attached thereto (i) the Amended and Restated Charter as in effect at the time of the Closing, (ii) the Company’s Bylaws as in effect at the
time of the Closing, (iii) resolutions approved by the Board of Directors of the Company authorizing the transactions contemplated hereby, (iv) resolutions approved by the Company’s stockholders in accordance with Section 4.1(c)
above, and (v) good standing certificates with respect to the Company from the applicable authority(ies) in Delaware and any other jurisdiction in which the Company is qualified to do business, dated as of a recent date before the Closing Date.

 4.2        Conditions to Obligations of the
Company.    The Company’s obligation to issue and sell the Shares at the Closing is subject to the satisfaction (or waiver by the Company), on or prior to the Closing Date, of the following conditions: 

(a)        Representations and Warranties
True.    The representations and warranties in Section 3 made by Purchaser shall be true and correct in all material respects as of the Closing Date. 

(b)        Performance of Obligations.    Purchaser
shall have performed and complied with all agreements and conditions herein required to be performed or complied with by Purchaser on or before the Closing Date. 

(c)        Investor Rights Agreement.    Purchaser
shall have executed and delivered the Investor Rights Agreement. 

(d)        Consents, Permits, and Waivers.    The
Company shall have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement. 

(e)        Lockup Agreement.    Purchaser shall have
executed and delivered a lockup agreement substantially in the form attached hereto as Exhibit C. 
  

	 	 5.
	 MISCELLANEOUS. 

  
 17.

 5.1        Withholding
Tax.    The parties acknowledge that payments with respect to the Shares made by the Company to Purchaser, if Purchaser is a Foreign Purchaser, may be subject to United States withholding tax. Purchaser, if Purchaser is a
Foreign Purchaser, shall timely provide to the Company two copies of IRS Form W-8ECI or IRS Form W-8BEN (or any successor form) to claim such an exemption or reduction in accordance with applicable law. 

5.2        Governing Law.    This Agreement shall be
governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without giving effect to conflict of law
principles thereof. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to
and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of San Diego, California. 
 5.3        Survival.    The representations, warranties, covenants and agreements made herein shall survive the closing of the
transactions contemplated hereby. All statements as to factual matters contained in any certificate or other instrument delivered by or on behalf of the Company pursuant hereto in connection with the transactions contemplated hereby shall be deemed
to be representations and warranties by the Company hereunder solely as of the date of such certificate or instrument. The representations, warranties, covenants and obligations of the Company, and the rights and remedies that may be exercised by
Purchaser, shall not be limited or otherwise affected by or as a result of any information furnished to, or any investigation made by or knowledge of, Purchaser or any of its representatives. 

5.4        Successors and Assigns.    Except as
otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon the parties hereto and their respective successors, assigns, heirs, executors and administrators and shall inure to the benefit of and be
enforceable by each person who shall be a holder of the Shares from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Shares specifying the full name and address of the
transferee, the Company may deem and treat the person listed as the holder of such Shares in its records as the absolute owner and holder of such Shares for all purposes. 

5.5        Entire Agreement.    This Agreement, the
exhibits and schedules hereto, the Investor Rights Agreement and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects

  
 18.

 
hereof and thereof and no party shall be liable for or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set
forth herein and therein. 

5.6        Severability.    In the event one or more
of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement
shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 

5.7        Amendment and Waiver.    This Agreement
may be amended or modified, and the obligations of the Company and the rights of the holders of the Shares under this Agreement may be waived, only upon the written consent of the Company and Purchaser. 

5.8        Delays or Omissions.    It is agreed that
no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement or the Investor Rights Agreement, shall impair any such right, power or remedy, nor
shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or waiver of or acquiescence in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver,
permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement or the Investor Rights Agreement or any waiver on such party’s part of any provisions or conditions of
this Agreement or the Investor Rights Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, the Investor Rights Agreement, the Amended and Restated
Charter, the Company’s Bylaws, or otherwise afforded to any party, shall be cumulative and not alternative. 
 5.9        Notices.    All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail, telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company and to Purchaser at the applicable address as set forth below or at such other address or electronic mail 

  
 19.

 
address as the Company or Purchaser may designate by ten (10) days advance written notice to the other party hereto. 

 

			
	 To the Company:
	  	 Regulus Therapeutics, Inc.
 3545 John Hopkins Court, Suite 210
 San Diego, California 92121

Attention: President and CEO

		
	 With a copy to:
	  	 Cooley LLP
 4401 Eastgate Mall
 San Diego, CA 92121

Attention: Thomas A. Coll, Esq.

		
	 To Investor:
	  	 AstraZeneca AB
 SE-431 83 Mölndal
 Sweden

Attention: Legal Department

		
	 With a copy to:
	  	 AstraZeneca UK Limited
 Strategic Planning and Business Development Alderley House,
 Alderley
Park,
 Macclesfield,
 Cheshire SK10 4T

5.10        Expenses.    Each party shall pay all
costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. 
 5.11        Titles and Subtitles.    The titles of the sections and subsections of this Agreement are for convenience of reference only
and are not to be considered in construing this Agreement. 

5.12        Counterparts.    This Agreement may be
executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Any or all parties may execute this Agreement by facsimile signature or scanned signature in PDF format and any
such facsimile signature or scanned signature, if identified, 

  
 20.

 
legible and complete, shall be deemed an original signature and each of the parties is hereby authorized to rely thereon. 

5.13        Broker’s Fees.    Each party hereto
represents and warrants that no agent, broker, investment banker, person or firm acting on behalf of or under the authority of such party hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or
indirectly in connection with the transactions contemplated herein. Each party hereto further agrees to indemnify each other party for any claims, losses or expenses incurred by such other party as a result of the representation in this
Section 5.13 being untrue. 

5.14        Pronouns.    All pronouns contained
herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 

5.15        California Corporate Securities
Law.    THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT
OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE 
 [THE
REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 21.

 IN WITNESS WHEREOF, the
parties hereto have executed the COMMON STOCK PURCHASE AGREEMENT as of the date set forth in the first paragraph hereof. 

 

									
	 COMPANY:
	 		 	 PURCHASER:

			
	 REGULUS THERAPEUTICS INC.
	 		 	 ASTRAZENECA AB

					
	 Signature:
	 	 /s/ Kleanthis G. Xanthopoulos
	 		 	 Signature:
	 	 /s/ Gunnar Olsson

					
	 Print Name:
	 	 Kleanthis G. Xanthopoulos, Ph.D.
	 		 	 Print Name:
	 	 Gunnar Olsson

					
	 Title:
	 	 President & CEO
	 		 	 Title:
	 	 VP & Head CVGI iMed

					
	 Address:
	 	 3545 John Hopkins Court, Suite 210
 San Diego, CA 92121
	 		 	 Address:
	 	 SE-431 83 Mölndal, Sweden

 EXHIBIT A 

INVESTOR RIGHTS AGREEMENT 

  
 REGULUS
THERAPEUTICS INC. 
 INVESTOR RIGHTS AGREEMENT 

 REGULUS THERAPEUTICS INC. 

INVESTOR RIGHTS AGREEMENT 
 THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of
[                        ], by and between Regulus Therapeutics Inc., a Delaware corporation (the
“Company”), and AstraZeneca AB, a limited liability company organized under the laws of Sweden (“Investor”). The Company and Investor may be referred to hereinafter collectively as the
“Parties” and each individually as a “Party.” 

RECITALS 
 WHEREAS, in connection with the purchase of shares of the Common Stock of the Company by Investor pursuant to that certain Common Stock Purchase Agreement dated as of August 14,
2012 (the “Purchase Agreement”), the parties desire to enter into this Agreement in order to grant registration rights, information rights and other rights to Investor as set forth below. 

NOW, THEREFORE, in consideration of these premises and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION
1.  DEFINITIONS. 
 Capitalized terms used herein and not defined elsewhere herein have the meanings set forth in
Exhibit A. 
 SECTION 2.  RESTRICTIONS ON TRANSFER. 

Investor shall not, directly or indirectly, sell, assign, transfer, pledge, hypothecate, or otherwise deal with or encumber or dispose of
in any way the Shares or Registrable Securities, whether in whole or in part, voluntarily or involuntarily, by operation of law or otherwise (each a “Transfer”), except in accordance with the terms and conditions set forth in
this Section 2. 
 2.1      Restrictions on
Transfer.    Except as set forth in Section 2.2, Investor agrees not to make any Transfer of the Shares or Registrable Securities unless and until: 

(a)        there is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 1. 

 (b)        (i) The
transferee has agreed in writing to be bound by the terms of this Agreement, (ii) Investor will have notified the Company of the proposed Transfer and will have furnished the Company with a detailed statement of the circumstances surrounding
the proposed Transfer, and (iii) if reasonably requested by the Company, Investor will have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such
shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. After the consummation of its Initial Offering, the Company will not
require any transferee pursuant to Rule 144 to be bound by the terms of this Agreement if the shares so transferred do not remain Registrable Securities hereunder following such transfer. 

2.2      Exempt Transfers.    Notwithstanding the provisions of
Section 2.1 above, no such restriction will apply to: 

(a)        a Transfer by Investor to an affiliate of Investor;
provided, however, that (i) such affiliate must have the resources, assets, experience, qualifications, permits and other rights necessary to perform under this Agreement and (ii) the transferee will agree in writing to be subject
to the terms of this Agreement to the same extent as if it were an original Party hereunder. 

(b)        a Transfer pursuant to a Change of Control of Investor.

 2.3      Stock Legends.    Each certificate
representing Shares or Registrable Securities will be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
“ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR
TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON

  
 2. 

 
WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(a)        The Company will be obligated to promptly reissue unlegended
certificates at the request of Investor if the Company has completed its Initial Offering and Investor has obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the
securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above will be removed only at such time as Investor is no longer subject to any
restrictions hereunder. 
 (b)        Any legend endorsed on an
instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities will be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal.

 SECTION 3.  COVENANTS OF THE COMPANY. 

3.1      Financial Information and Reporting. 

(a)        The Company will cause to be maintained complete books and
records accurately reflecting the accounts, business and transactions of the Company on a calendar-year basis and with sufficient detail and completeness customary and usual for businesses of the type engaged in by the Company. The Company’s
books and records and financial statements will be in accordance with U.S. generally accepted accounting principles. The Company’s financial statements will be audited annually by an independent nationally recognized public accounting firm
approved by the Board of Directors of the Company (the “Board”). 

(b)        As soon as practicable after the end of each fiscal year of
the Company, and in any event when first delivered to the holders of Series A Convertible Preferred Stock of the Company (the “Series A Preferred Stock”) or their designees, the Company will furnish Investor a balance sheet
of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted
therein) and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. 
 (c)        The Company will furnish Investor, as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal
year of the Company, and in any event when first delivered to the holders of Series A Preferred Stock or their designees, a balance sheet of the Company as of the end of each such quarterly period, and a statement of income and a statement of cash
flows of the Company for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently 

  
 3. 

 
applied (except as noted therein), with the exception that year-end audit adjustments may not have been made. 

(d)        The Company will furnish Investor: (i) the annual budget
for each fiscal year approved by the Board, promptly following the approval thereof by the Board, with competitively sensitive information redacted therefrom (and as soon as available, any subsequent revisions thereto); and (ii) on an annual
basis promptly following the end of the Company’s first fiscal quarter, an up to date capitalization table. 
 (e)        The Company will provide to Investor any financial information reasonably requested by Investor, and the Company will make its management
available to Investor for reasonable inquiries regarding its financials. 

3.2      Confidentiality of Records.    Investor agrees to use
the same degree of care as Investor uses to protect its own confidential information to keep confidential and not disclose to any party any information furnished to Investor pursuant to Section 3.1 hereof that the Company identifies as being
confidential or proprietary (so long as such information is not in the public domain), except that Investor may disclose such proprietary or confidential information (i) to any affiliate, partner, subsidiary or parent of Investor as long as
such affiliate, partner, subsidiary or parent is advised of and agrees or has agreed to be bound by the confidentiality provisions of this Section 3.2 or comparable restrictions; (ii) to its attorneys, accountants, consultants and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, if such person agrees to be bound by the provisions of this Section 3.2 or comparable restrictions; (iii) at such
time as it enters the public domain through no fault of Investor; (iv) that is communicated to Investor by a third party free of any obligation of confidentiality; (v) that is developed by Investor or its agents independently of and
without reference to any confidential information communicated by the Company; or (vi) as required by applicable law. Upon request by the Company, Investor agrees to enter into a separate confidentiality agreement with the Company. Nothing in
this Agreement shall preclude or in any way restrict Investor from investing or participating in any particular enterprise, regardless of whether such enterprise has products or services that compete with those of the Company; provided,
however, that Investor shall not disclose any confidential information of the Company to any such enterprise. 
 SECTION
4.  REGISTRATION RIGHTS; MARKET STAND-OFF. 
 4.1      Piggyback
Registrations.    Other than in connection with the Initial Offering, the Company will notify all Holders of Registrable Securities in writing at least fifteen (15) days prior to the filing of any registration statement
under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding Special Registration
Statements) and will afford each such Holder an opportunity to include in such registration 

  
 4. 

 
statement all or part of such Registrable Securities held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by
it will, within fifteen (15) days after the above-described notice from the Company, so notify the Company in writing. Such notice will state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides
not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder will nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement
or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 
 (a)      Underwriting.    If the registration statement of which the Company gives notice under this Section 4.1 is for an underwritten
offering, the Company will so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include Registrable Securities in a registration pursuant to this Section 4.1 will be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting will
enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this Agreement, if the underwriter determines in good faith that
marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting will be allocated, first, to the Company; and second, to the Holders on a pro rata basis based on
the total number of Registrable Securities held by the Holders; provided, however, that such reduction will not be permitted unless such registration does not include shares of any other selling stockholders. If any Holder disapproves
of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any
Registrable Securities excluded or withdrawn from such underwriting will be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability company or corporation, the partners, retired partners, members,
retired members and stockholders of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing persons will be deemed to be a single
“Holder,” and any pro rata reduction with respect to such “Holder” will be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,”
as defined in this sentence. 
 (b)      Right to Terminate
Registration.    The Company will have the right to terminate or withdraw any registration initiated by it under this Section 4.1 whether or not any Holder has elected to include securities in such registration. The
Registration Expenses of such withdrawn registration will be borne by the Company in accordance with Section 4.3 hereof. 

  
 5. 

 4.2      Form S-3 Demand
Registrations.    In case the Company receives from any Holder or Holders of Registrable Securities (the “Initiating Holders”) a written request or requests that the Company effect a registration on
Form S-3 (or any successor to Form S-3) or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company
will: 
 (a)        promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders of Registrable Securities; and 

(b)        as soon as practicable, effect such registration and all such
qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with
all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided,
however, that the Company will not be obligated to effect any such registration, qualification or compliance pursuant to this Section 4.2: 
 (i)        if Form S-3 is not available for such offering by the Holders; 

(ii)        if the Holders, together with the holders of any other
securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than fifteen million dollars ($15,000,000); 

(iii)        if within thirty (30) days of receipt of a written
request from any Holder or Holders pursuant to this Section 4.2, the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special
Registration Statement; 
 (iv)        if the Company will
furnish to the Holders a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected
at such time, in which event the Company will have the right to defer the filing of the Form S-3 registration statement for a period of not more than one hundred twenty (120) days after receipt of the request of the Holder or Holders under
this Section 4.2; provided, that such right to delay a request will be exercised by the Company not more than twice in any twelve (12) month period; 

(v)        if the Company has, within the twelve (12) month period
preceding the date of such request, already effected one (1) registration on Form S-3 for the Holders pursuant to this Section 4.2; 

  
 6. 

 (vi)        if the Company
has already effected two (2) registrations on Form S-3 for the Holders pursuant to this Section 4.2; or 
 (vii)        in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of
process in effecting such registration, qualification or compliance. 

(c)        Subject to the foregoing, the Company will file a
Form S-3 registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. 

4.3      Expenses of Registration.    Except as specifically
provided herein, all Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Section 4.1 or 4.2 herein will be borne by the Company. All Selling Expenses incurred in connection with any
registrations hereunder, will be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company will not, however, be required to pay for expenses of any registration proceeding
begun pursuant to Section 4.2, the request of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning the Company of which the Initiating Holders were
not aware at the time of such request or (b) the Holders of a majority of Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company will be
obligated pursuant to Section 4.2(b)(v), as applicable, to undertake any subsequent registration, in which event such right will be forfeited by all Holders). If the Holders are required to pay the Registration Expenses, such expenses will be
borne by the holders of securities (including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn
offering pursuant to clause (a) above, then such registration will not be deemed to have been effected for purposes of determining whether the Company will be obligated pursuant to Section 4.2(b)(v) to undertake any subsequent
registration. 
 4.4      Obligations of the
Company.    Whenever required to effect the registration of any Registrable Securities, the Company will, as expeditiously as reasonably possible: 

(a)        prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use all commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for up to thirty (30) days or, if earlier, until the Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating
Holders and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may 

  
 7. 

 
delay the filing or effectiveness of any registration statement or suspend the use of any registration statement (and the Holders hereby agree not to offer or sell any Registrable Securities
pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that there is or may be in existence material nonpublic information or events involving the Company, the failure of which to be disclosed in the
prospectus included in the registration statement could result in a Violation (as defined below). In the event that the Company will exercise its right to delay the filing or effectiveness or suspend the use of a registration hereunder, the
applicable time period during which the registration statement is to remain effective will be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive
sixty (60) days with the consent of the Holders of a majority of the Registrable Securities registered under the applicable registration statement, which consent will not be unreasonably withheld. If so directed by the Company, all Holders
registering shares under such registration statement will (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after receiving notice of such
delay or suspension; and (ii) use their commercially reasonable efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to
such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company will not be required to file, cause to become effective or maintain the effectiveness of any registration statement other than a
registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 

(b)        Prepare and file with the SEC such amendments and supplements
to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such
registration statement for the period set forth in subsection (a) above. 

(c)        Furnish to the Holders such number of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d)        Use its commercially reasonable efforts to register and
qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as will be reasonably requested by the Holders; provided that the Company will not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (e)        In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the managing 

  
 8. 

 
underwriter(s) of such offering. Each Holder participating in such underwriting will also enter into and perform its obligations under such an agreement. 

(f)        Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company will use
commercially reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then existing. 

(g)        Use its commercially reasonable efforts to furnish, on the
date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants
of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 

4.5      Delay of Registration; Furnishing Information. 

(a)        No Holder will have any right to obtain or seek an injunction
restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 4. 

(b)        It will be a condition precedent to the obligations of the
Company to take any action pursuant to Section 4.1 or 4.2 that the selling Holders will furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such
securities as will be required to effect the registration of their Registrable Securities. 

(c)        The Company will have no obligation with respect to any
registration requested pursuant to Section 4.2 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated
aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 4.2. 
 4.6      Indemnification.     In the event any Registrable Securities are included in a registration statement under Section 4.1 or 4.2:

  
 9. 

 (a)        To the extent
permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members, stockholders, officers and directors of each Holder, as applicable, any underwriter (as defined in the Securities Act) for such Holder and each
person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act,
the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection
with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, member, stockholder, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them
in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that the indemnity agreement contained in this Section 4.6(a) will not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent will not be unreasonably withheld, nor will the Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, member,
officer, director, underwriter or controlling person of such Holder. 

(b)        To the extent permitted by law, each Holder will, if
Registrable Securities held by such Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if
any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder, as applicable, selling securities under such registration statement or any of such other Holder’s partners, directors or officers or
any person who controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or
controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based
upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus
contained therein or any amendments or 

  
 10.

 
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon
and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other
expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any
such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 4.6(b) will not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent will not be unreasonably withheld; provided further, that in no event will any indemnity under
this Section 4.6 exceed the net proceeds from the offering actually received by such Holder, as applicable. 
 (c)        Promptly after receipt by an indemnified party under this Section 4.6 of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 4.6, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party
will have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an indemnified party will have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying
party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a
reasonable time of the commencement of any such action will relieve such indemnifying party of any liability to the indemnified party under this Section 4.6 to the extent, and only to the extent, prejudicial to its ability to defend such
action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 4.6. 

(d)        If the indemnification provided for in this Section 4.6
is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder,
will to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) or 

  
 11.

 
Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party will be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, that in no event will any contribution
by a Holder, as applicable, hereunder exceed the net proceeds from the offering received by such Holder, as applicable. 
 (e)        The obligations of the Company and Holders under this Section 4.6 will survive completion of any offering of Registrable Securities, as
applicable, in a registration statement and, with respect to liability arising from an offering to which this Section 4.6 would apply that is covered by a registration filed before termination of this Agreement, such termination. No
indemnifying party, in the defense of any such claim or litigation, will, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 
 4.7      Assignment of Registration Rights.    The rights to cause the Company to register Registrable Securities pursuant to this Section 4
may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired
member, stockholder or other affiliate of a Holder that is a corporation, partnership or limited liability company, (b) acquires all of such Holders Registrable Securities in connection with the sale of all or substantially all of such
Holder’s business, or (c) acquires at least two hundred thousand (200,000) shares of Registrable Securities (as adjusted for stock splits and combinations); or (d) is an entity affiliated by common control (or other related
entity) with such Holder provided, however, (i) the transferor will, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with
respect to which such registration rights are being assigned and (ii) such transferee will agree to be subject to all restrictions set forth in this Agreement. 

4.8      Limitation on Subsequent Registration Rights.    Except
as otherwise provided herein, after the date of this Agreement, the Company will not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of
shares of the Company’s capital stock, or to include such shares in a registration statement that would reduce the number of shares includable by the Holders. 

  
 12.

 4.9      “Market Stand-Off”
Agreement.    Each Holder hereby agrees that such Holder, as the case may be, will not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) during the 365-day period following the effective date of the registration statement pertaining
to the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 365-day period, as the underwriters or the Company will request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any
successor rule); provided, that all officers, directors of the Company and all stockholders of the Company holding in the aggregate at least 1% of the Company’s equity securities on a fully-diluted basis are bound by and have entered into
similar agreements. The obligations described in this Section 4.9 will not apply to a Special Registration Statement. 
 4.10      Agreement to Furnish Information.    Each Holder hereby agrees to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriter that are consistent with such Holder’s obligations under Section 4.9, as applicable, or that are necessary to give further effect thereto. In addition, if requested by the Company or the
representative of the underwriters of Common Stock (or other securities) of the Company, each Holder will provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection
with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in Section 4.9 and this Section 4.10 will not apply to a Special
Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said day period. Each Holder agrees that any transferee
of any shares of Registrable Securities will be bound by Sections 4.9 and 4.10. The underwriters of the Company’s stock are intended third party beneficiaries of Sections 4.9 and 4.10 and will have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. 
 4.11    Rule 144
Reporting.    With a view to making available to the Holders, as applicable, the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration,
the Company agrees to use its best efforts to: 

(a)        Make and keep public information available, as those terms are
understood and defined in Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general
public; 
 (b)        File with the SEC, in a timely manner, all
reports and other documents required of the Company under the Exchange Act; and 

  
 13.

 (c)        So long as a
Holder owns any Registrable Securities, as applicable, furnish to such Holder forthwith upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144, and of the Exchange Act (at any time
after it has become subject to such reporting requirements); a copy of the most recent annual or quarterly report of the Company filed with the SEC; and such other reports and documents as a Holder may reasonably request in connection with availing
itself of any rule or regulation of the SEC allowing it to sell any such securities without registration. 

4.12    Termination of Registration Rights.    The right of any Holder to
request registration or inclusion of Registrable Securities in any registration pursuant to Sections 4.1 or 4.2 hereof will terminate upon the earlier of: (i) the date three (3) years following the consummation of the Initial Offering; or
(ii) following the consummation of the Initial Offering, such time as all Registrable Securities held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during any ninety (90) day period. Upon such
termination, such shares will cease to be “Registrable Securities” hereunder for all purposes. 
 SECTION
5.  MISCELLANEOUS. 
 5.1      Governing
Law.    This Agreement will in all respects be governed by and construed in accordance with the substantive laws of the State of California, without regard to its choice of law rules. 

5.2      Successors and Assigns.    Except as otherwise
expressly provided herein, the provisions hereof will inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and will inure to the benefit of and be enforceable
by each person who will be a holder of Registrable Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and
address of the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price.

 5.3      Entire Agreement.    This Agreement,
including the exhibits and schedules hereto, constitutes the entire agreement between the Company and Investor with respect to the specific subject matter hereof, and supersedes all prior and contemporaneous agreements, representations, and
understandings of the parties with respect to such specific subject matter. No party hereto will be liable or bound to the other in any manner by any warranties, representations or covenants with respect to the subject matter hereof except as
specifically set forth herein. 

5.4      Severability.    If one or more provisions of this
Agreement are held by a proper court or arbitral tribunal to be unenforceable under applicable law, the unenforceable portions of such provisions, or such provisions in their entirety, to the extent necessary and permitted by

  
 14.

 
law, will be severed herefrom, and the balance of this Agreement will be enforceable in accordance with its terms. 

5.5      Amendment and Waiver.    Except as otherwise expressly
provided, this Agreement may be amended or modified, and the rights and obligations under this Agreement may be waived, only upon the written consent of the Company and Investor. 

5.6      Delays or Omissions.    It is agreed that no delay or
omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement will impair any such right, power, or remedy, nor will it be construed to be a waiver of any such
breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s
part of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and will be effective only to the extent specifically set forth in such
writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, will be cumulative and not alternative. 
 5.7      Notices.    Except where otherwise specifically provided in this Agreement, all notices, requests, consents, approvals and statements will
be in writing and will be deemed to have been properly given by (i) personal delivery, (ii) electronic facsimile transmission, (iii) electronic mail, or by (iv) nationally recognized overnight courier service, addressed in each
case, to the intended recipient as set forth below: 
  

			
	 To the Company:
	  	 Regulus Therapeutics, Inc.
 3545 John Hopkins Court, Suite 210
 San Diego, California 92121

Attention: President and CEO

		
	 With a copy to:
	  	 Cooley LLP
 4401 Eastgate Mall
 San Diego, CA 92121

Attention: Thomas A. Coll, Esq.

		
	 To Investor:
	  	 AstraZeneca AB
 SE-431 83 Mölndal
 Sweden

Attention: Legal Department

		
	 With a copy to:
	  	 AstraZeneca UK Limited
 Strategic Planning and Business Development
 Alderley
House,

  
 15.

			
		  	 Alderley Park,
 Macclesfield,
 Cheshire SK10 4T

 Such notice, request, demand, claim or other communication will be deemed to have been duly given on
(a) the date of personal delivery, (b) the date actually received if by facsimile or electronic mail; or (c) on the third business day after delivery to a nationally recognized overnight courier service, as the case may be. Either
Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth. 

5.8      Fees and Expenses.    Each party will pay all costs and
expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. If any action at law or in equity is necessary to enforce or interpret the terms of any of this Agreement, the prevailing party will be
entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. For purposes of this Section 5.8, “prevailing party” means the net winner of a
dispute, taking into account the claims pursued, the claims on which the pursuing party was successful, the amount of money sought, the amount of money awarded, and offsets or counterclaims pursued (successfully or unsuccessfully) by the other
Party. If a written settlement offer is rejected and the judgment or award finally obtained is equal to or more favorable to the offeror than an offer made in writing to settle, the offeror is deemed to be the prevailing party from the date of the
offer forward. 
 5.9      Titles and Subtitles; Form of Pronouns; Construction
and Definitions.    The titles of the Sections and paragraphs of this Agreement are for convenience only and are not to be considered in construing this Agreement. All pronouns used in this Agreement will be deemed to include
masculine, feminine and neuter forms, the singular number includes the plural and the plural number includes the singular and will not be interpreted to preclude the application of any provision of this Agreement to any individual or entity. Unless
the context otherwise requires, (i) each reference in this Agreement to a designated “Section,” “Schedule,” “Exhibit,” or “Appendix” is to the corresponding Section, Schedule, Exhibit, or Appendix of or
to this Agreement; (ii) the word “or” will not be applied in its exclusive sense; (iii) “including” will mean “including, without limitation”; (iv) references to “$” or “dollars” will
mean the lawful currency of the United States; and (v) “herein,” “hereof,” “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.
References in this Agreement to particular sections of the Securities Act or to any provisions of California law will be deemed to refer to such sections or provisions as they may be amended or succeeded after the date of this Agreement. 

5.10    Counterparts.    This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which together will constitute one and the 

  
 16.

 
same instrument, and will become effective when there exist copies hereof which, when taken together, bear the authorized signatures of each of the parties hereto. Only one such counterpart
signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 
 5.11    Aggregation of Stock.    All shares of Registrable Securities held or acquired by affiliated entities or persons or persons or entities under common
management or control will be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 5.12    Specific Performance.    The failure of either party to this Agreement to perform its agreements and covenants hereunder, including but not limited
to Section 4, may cause irreparable injury to the other party to this Agreement for which monetary damages, even if available, will not be an adequate remedy. Accordingly, each of the parties hereto hereby consents to the granting of equitable
relief (including specific performance and injunctive relief) by any court of competent jurisdiction to enforce any Party’s obligations hereunder. The parties further agree to waive any requirement for the securing or posting of any bond in
connection with the obtaining of any such equitable relief and that this Section 5.12 is without prejudice to any other rights that the Company and Investor may have for any failure to perform this Agreement. 

5.13    Termination.    This Agreement will terminate and be of no further
force or effect upon the earlier of (i) a Liquidation Event, Acquisition or Asset Transfer; or (ii) the date three (3) years following the Closing Date (as defined in the Purchase Agreement). 

[THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 17.

 IN WITNESS WHEREOF, the
parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 
 COMPANY: 
  

			
	 REGULUS THERAPEUTICS INC.

		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 

 INVESTOR: 
  

			
	 ASTRAZENECA AB

		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 

 EXHIBIT A 
 DEFINITIONS 

1.1    “Change of Control” means, with respect to Investor, the
earlier of (x) the public announcement of and (y) the closing of: (a) a merger, reorganization or consolidation involving Investor in which its shareholders immediately prior to such transaction would hold less than 50% of the
securities or other ownership or voting interests representing the equity of the surviving entity immediately after such merger, reorganization or consolidation, or (b) a sale to a third party of all or substantially all of Investor’s
assets or business relating to this Agreement. Investor will notify the Company within two (2) Business Days of entering into an agreement which, if consummated, would result in a Change of Control. 

1.2    “Common Stock” means the Common Stock of the Company.

 1.3    “Exchange Act” means the Securities Exchange Act of
1934, as amended. 
 1.4    “Form S-3” means such form under
the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other
documents filed by the Company with the SEC. 
 1.5    “Holder”
means Investor so long as it owns of record Registrable Securities that have not been sold to the public, or any assignee of record of such Registrable Securities in accordance with Section 4.7 hereof. 

1.6    “Initial Offering” means the Company’s first firm
commitment underwritten public offering of its Common Stock registered under the Securities Act. 

1.7    “Register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or
document. 
 1.8    “Registrable Securities” means
(a) the Shares; and (b) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, such above-described securities. Notwithstanding the foregoing, Registrable Securities will not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144, (ii) sold in
a private transaction in which the transferor’s rights under Section 4 of this Agreement are not assigned or (iii) eligible for resale pursuant to Rule 144 without volume limitations. 

 1.9    “Registration Expenses”
means all expenses incurred by the Company in complying with Sections 4.1 or 4.2, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and
disbursements not to exceed ten thousand dollars ($10,000) of a single special counsel for the Holders, if applicable, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding
the compensation of regular employees of the Company which will be paid in any event by the Company). 

1.10    “Rule 144” means Rule 144 promulgated under the Securities
Act, as in effect from time to time. 
 1.11    “SEC” means
the Securities and Exchange Commission. 
 1.12    “Securities Act”
means the Securities Act of 1933, as amended. 
 1.13    “Selling
Expenses” means all underwriting discounts and selling commissions applicable to the sale. 

1.14    “Shares” means the shares of Common Stock of the Company
issued pursuant to the Purchase Agreement held from time to time by Investor and its permitted assigns. 

1.15    “Special Registration Statement” means (i) a registration
statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in
such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 

 EXHIBIT B 

LEGAL OPINION 

 EXHIBIT C 

LOCKUP AGREEMENTCollaboration and License Agreement

 Exhibit 10.39 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

 
 COLLABORATION AND LICENSE AGREEMENT 

by and between 
 REGULUS THERAPEUTICS INC. 
 and 

BIOGEN IDEC MA Inc. 
  

 
  

Confidential 

 TABLE OF CONTENTS 

 

					
	 	  	 	  	Page
			
	Article 1	  	DEFINITIONS	  	1
			
	Article 2	  	COLLABORATION	  	6
			
	    2.1	  	Research.	  	6
			
	    2.2	  	Reports. Research and Collaboration Data	  	6
			
	    2.3	  	Following Completion of the Research.	  	6
			
	Article 3	  	COLLABORATION COORDINATION	  	7
			
	    3.1	  	Research Coordination.	  	7
			
	Article 4	  	MATERIAL TRANSFER	  	7
			
	    4.1	  	Materials.	  	7
			
	    4.2	  	Ownership.	  	7
			
	    4.3	  	Use.	  	7
			
	    4.4	  	Delivery.	  	7
			
	    4.5	  	Return of Leftover Material.	  	7
			
	Article 5	  	LICENSES AND INTELLECTUAL PROPERTY OWNERSHIP	  	7
			
	    5.1	  	License Grants to BI.	  	7
			
	    5.2	  	License Grants to Regulus.	  	8
			
	    5.3	  	Ownership of and Rights to Intellectual Property.	  	11
			
	    5.4	  	No Other Rights.	  	12
			
	Article 6	  	FINANCIAL PROVISIONS	  	12
			
	    6.1	  	Research Term Expenses.	  	12
			
	    6.2	  	Collaboration Fee.	  	12
			
	    6.3	  	Milestones.	  	12
			
	    6.4	  	Payment Provisions Generally.	  	13
			
	Article 7	  	INTELLECTUAL PROPERTY PROTECTION AND RELATED MATTERS	  	13
			
	    7.1	  	Filing, Prosecution, Maintenance and Enforcement of Patent Rights.	  	13
			
	    7.2	  	Enforcement of Patent Rights.	  	16
			
	    7.3	  	Other Infringement Resolutions.	  	18

  
 ii 

 TABLE OF CONTENTS (cont’d) 

 

					
	 	  	 	  	Page
			
	     7.4
	  	Common Interest.	  	18
			
	 Article 8
	  	CONFIDENTIALITY	  	19
			
	     8.1
	  	Confidential Information.	  	19
			
	     8.2
	  	Publication Review.	  	20
			
	 Article 9
	  	TERM AND TERMINATION	  	20
			
	     9.1
	  	Term.	  	20
			
	     9.2
	  	Termination for Cause.	  	20
			
	     9.3
	  	Termination for Convenience.	  	22
			
	     9.4
	  	Rights in Bankruptcy.	  	22
			
	     9.5
	  	Effect of Expiration or Termination; Survival.	  	22
			
	 Article 10
	  	REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION	  	23
			
	     10.1
	  	Mutual Representations and Warranties.	  	23
			
	     10.2
	  	Regulus Covenants, Representations and Warranties.	  	23
			
	     10.3
	  	BI Covenants, Representations and Warranties.	  	24
			
	     10.4
	  	Warranty Disclaimer.	  	24
			
	     10.5
	  	No Consequential Damages.	  	24
			
	     10.6
	  	Indemnification and Insurance.	  	24
			
	 Article 11
	  	MISCELLANEOUS PROVISIONS	  	26
			
	     11.1
	  	Governing Law.	  	26
			
	     11.2
	  	Assignment.	  	26
			
	     11.3
	  	Amendments.	  	26
			
	     11.4
	  	Notices.	  	26
			
	     11.5
	  	Force Majeure.	  	27
			
	     11.6
	  	Compliance with Applicable Laws.	  	28
			
	     11.7
	  	Independent Contractors.	  	28
			
	     11.8
	  	Further Assurances.	  	28
			
	     11.9
	  	No Strict Construction.	  	28
			
	     11.10
	  	Headings.	  	28
			
	     11.11
	  	No Implied Waivers; Rights Cumulative.	  	28
			
	     11.12
	  	Severability.	  	28
			
	     11.13
	  	No Third Party Beneficiaries.	  	29

  
 iii

 TABLE OF CONTENTS (cont’d) 

 

					
	 	  	 	  	Page
			
	     11.14
	  	Execution in Counterparts.	  	29

  

  
 iv 

 SCHEDULES AND EXHIBITS 

 

			
	 Schedule A
	    	Research Plan
		
	 Schedule B
	    	Materials
		
	 Schedule C
	    	Existing Licensees
		
	 EXHIBIT I
	    	Note Purchase Agreement

  
 v 

 COLLABORATION AND LICENSE AGREEMENT 

This Collaboration and License Agreement (this “Agreement”) dated August 15, 2012, (the “Effective
Date”) is by and between Regulus Therapeutics Inc., a Delaware corporation with its principal address at 3545 John Hopkins Ct., Suite 210, San Diego, CA 92121 (“Regulus”), and Biogen Idec MA Inc., along with its
Affiliates, a Massachusetts corporation with its principal address at 133 Boston Post Road, Weston, MA 02493 (“BI”). Regulus and BI may each be referred to herein individually as a “Party” and collectively as the
“Parties.” 
 INTRODUCTION 
 WHEREAS, Regulus owns or otherwise controls certain intellectual property relating to microRNAs; 

WHEREAS, BI owns or otherwise controls certain proprietary material in the form of human samples including multiple sclerosis patient serum (as set forth
in further detail in the Research Plan, the “Samples”); and 
 WHEREAS, Regulus and BI are interested in collaborating on the
terms and conditions set forth herein to investigate microRNA biomarkers for MS using circulating microRNAs in the Samples, and, in granting each other licenses to intellectual property developed pursuant to this Agreement on the terms and
conditions set forth herein; 
 WHEREAS, simultaneously with the execution of this Agreement, the Parties are executing a Note Purchase
Agreement and the Convertible Promissory Note (collectively the “Note”) of even date herewith in the form attached hereto as Exhibit I. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby agree as follows: 
 Article 1 
 DEFINITIONS 
 When used in this Agreement, each of the following terms shall have the
meanings set forth in this Article 1: 
 1.1 “Affiliate” shall mean, with respect to a subject entity, another
entity that controls, is controlled by, or is under common control with such subject entity, for so long as such control exists. For purposes of this definition only, “control” shall mean beneficial ownership (direct or indirect) of at
least fifty percent (50%) of the equity securities of the entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, in the election of the corresponding managing authority). 

1.2 “Agreement Term” shall mean the period beginning on the Effective Date and ending on the expiration or termination of this
Agreement pursuant to Article 9 hereof. 

  
 -1-

 1.3 “Applicable Law” shall mean the applicable laws, rules and regulations,
including any rules, regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time in the Territory. 
 1.4 “Bankruptcy Code” shall mean Title 11, United States Code, as amended, or analogous provisions of Applicable Law outside the United States. 

1.5 “BI Research Collaboration IP” shall mean all Research Collaboration IP that is Invented solely by BI or Third Parties acting on
BI’s behalf. 
 1.6 “Business Day” shall mean a day on which banking institutions in Boston, Massachusetts, and San Diego,
California, are open for business. 
 1.7 “Calendar Quarter” shall mean each three month period ending on each of
March 31, June 30, September 30 and December 31. 
 1.8 “Commercially Reasonable Efforts” shall mean the
carrying out of obligations in a diligent and sustained manner using such effort and employing such resources as would normally be exerted or employed by a similarly situated biopharmaceutical company for a product of similar strategic importance,
and at a similar stage of its product life, based on conditions then prevailing. 
 1.9 “Confidential Information” shall mean,
with respect to each Party, proprietary data or information that belong in whole or in part to such Party, its Affiliates or sublicensees, including, without limitation, (i) in the case of Regulus, all Regulus Background IP and Regulus Research
Collaboration IP, (ii) in the case of BI, all BI Research Collaboration IP, and (iii) any information designated as Confidential Information of such Party hereunder, in all cases that, if disclosed in writing, is marked with the words
“Confidential,” “Proprietary” or words of similar import, and if disclosed orally or visually, is described in reasonable detail in a notice sent by the disclosing Party to the receiving Party within thirty (30) days of the
oral or visual disclosure requesting that such information be treated as Confidential Information hereunder; provided, however, that, if information is orally disclosed to or visually observed by a Party it shall constitute Confidential
Information if it would be apparent to a reasonable person, familiar with the business of such Party and the industry in which it operates, that such information is of a confidential or proprietary nature the maintenance of which is or would likely
be important to such Party. Notwithstanding the foregoing, the Parties agree that all Research Collaboration Data shall be deemed the Confidential Information of BI, and Regulus and BI shall be deemed the “receiving Party” and the
“disclosing Party,” respectively, with respect thereto. Confidential Information shall not include information that the receiving Party can demonstrate by competent documentary evidence: 

(a) was known by the receiving Party or its Affiliates prior to its date of disclosure to the receiving Party (or, in the case of
Research Collaboration Data, prior to the date generated in the course and as a result of the Research) as evidenced by the receiving Party’s pre-existing written records; or 

(b) either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party or its
Affiliates by sources other than the 

  
 -2-

 
disclosing Party rightfully in possession of the Confidential Information unless such disclosure is made subject to a confidentiality agreement; or 

(c) either before or after the date of the disclosure to the receiving Party or its Affiliates becomes published or generally known to the
public (including information known to the public through the sale of products in the ordinary course of business) through no act or omission in breach of this Agreement or negligence on the part of the receiving Party (including, for purposes of
this clause (c), its Affiliates or its sublicensees); or 
 (d) is independently developed by or for the receiving Party or
its Affiliates without reference to or reliance upon the Confidential Information as shown by contemporaneously-maintained written records. 

1.10 “Control” or “Controlled” shall mean with respect to any (a) material, item of information, method, data or
other Know-How, or (b) intellectual property right, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party access and/or a license as
provided herein under such item or right without violating the terms of any agreement or other arrangement with any Third Party existing before or after the Effective Date. 
 1.11 “Executive Officers” shall mean the Vice President Research of Translational Sciences of BI (or an executive of BI designated by such Vice President) and the Chief Executive Officer
of Regulus (or an executive of Regulus designated by such Chief Executive Officer). 
 1.12 “Existing Licensee” shall mean any
licensee of Regulus to which Regulus has granted, pursuant to an agreement entered into prior to the Effective Date or entered into prior to the date that BI has completed the transfer of Materials pursuant to Section 4.1 (an “Existing
Licensee Agreement”), rights or an option to obtain rights to products incorporating, utilizing or targeting miRNAs. All Existing Licensees as of the Effective Date are listed on Schedule C, which Schedule C shall be updated by Regulus
promptly following the date that BI completes the transfer of Materials pursuant to Section 4.1. 
 1.13 “FDA” shall mean
the United States Food and Drug Administration, or a successor agency in the United States with responsibilities comparable to those of the United States Food and Drug Administration. 
 1.14 “Invented” shall mean the act of invention by inventors, as determined in accordance with rules and guidelines regarding inventorship as established under United States patent law,
including case law and regulations associated therewith, whether or not the invention or discovery so invented is patentable. 
 1.15
“Joint Research Collaboration IP” shall mean all Research Collaboration IP that is Invented jointly by BI and Regulus or by Third Parties acting on their behalf. 
 1.16 “Know-How” shall mean any non-public, proprietary invention, discovery, process, method, composition, formula, procedure, protocol, technique, result of experimentation or
testing, information, data (but in no event Research Collaboration Data), material, technology or 

  
 -3-

 
other know-how, whether or not patentable or copyrightable. Know-How shall not include any Patent Rights with respect thereto. 
 1.17 “Materials” shall mean the samples described in the attached Schedule B and other materials provided pursuant to Section 4.1. 

1.18 “MicroRNA” or “miRNA” shall mean a short ribonucleic acid (RNA) molecule present in eukaryotic cells
that are known as post-transcriptional regulators that bind to complementary sequences on target messenger RNA transcripts (mRNAs) typically resulting in translational repression or target degradation and gene silencing. 

1.19 “miRNA Products” shall mean any product or product candidate employing, based on, utilizing or comprising any one or more
Research Collaboration MicroRNAs or any product or product candidate that is an agonist or antagonist of one or more Research Collaboration MicroRNAs, in all cases in relevant amounts to treat, prevent or diagnose a disease, disorder or condition.

 1.20 “MS” shall mean multiple sclerosis and all sub-indications (e.g. relapsing remitting multiple sclerosis,
secondary progressive multiple sclerosis) and symptoms related to MS. 
 1.21 “Non-miRNA Product” shall mean any product or
product candidate employing, based on, utilizing or comprising any Research Collaboration IP, excluding any and all miRNA Products. 
 1.22
“Note” shall mean the promissory note issued according to the Note Purchase Agreement dated August 15, 2012 between BI and Regulus, along with the Note Purchase Agreement, inclusive of all amendments thereto. 

1.23 “Patent Rights” shall mean (a) patents, patent applications and similar government-issued rights protecting inventions in any
country or jurisdiction however denominated, (b) all priority applications, divisionals, continuations, substitutions, continuations-in-part of and similar applications claiming priority to any of the foregoing, and (c) all patents and
similar government-issued rights protecting inventions issuing on any of the foregoing applications, together with all registrations, reissues, renewals, re-examinations, confirmations, supplementary protection certificates, and extensions of any of
(a), (b) or (c), in any country or region. 
 1.24 “Regulatory Approval” shall mean any approval, product and
establishment license, registration or authorization of any Regulatory Authority necessary or required for the commercial manufacture, distribution, storage, transport, marketing, promotion, offer for sale, use, import, export, and sale of a product
in a regulatory jurisdiction, including, to the extent legally required to market and sell the product in such regulatory jurisdiction, separate pricing and reimbursement approvals from the applicable Regulatory Authority. 

1.25 “Regulatory Authority” shall mean the FDA, or any counterpart of the FDA outside the United States, or any other national,
supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity involved in granting Regulatory Approval for a product in a regulatory jurisdiction within the Territory. 

  
 -4-

 1.26 “Regulus Background IP” shall mean all Patent Rights and Know-How Controlled, owned,
and/or licensed by Regulus on the Effective Date or during the Agreement Term, other than Regulus Research Collaboration IP, that is useful to develop, make, use or sell miRNA Products for the diagnosis of MS, or treatment on non-MS indications.

 1.27 “Regulus Research Collaboration IP” shall mean all Research Collaboration IP that is Invented solely by Regulus or
Third Parties acting on Regulus’s behalf. 
 1.28 “Related Party” shall mean a Party’s Affiliates and Third Party
sublicensees. 
 1.29 “Research” shall mean any and all activities to identify miRNA biomarkers for MS using circulating miRNAs
in MS patient serum and all other activities set forth in the Research Plan. When used as a verb, “Research” shall mean to engage in Research. 
 1.30 “Research Collaboration Data” shall mean all data arising out of activities conducted by or on behalf of either Party or jointly by or on behalf of the Parties under the Research
Plan. 
 1.31 “Research Collaboration IP” shall mean all Patent Rights and Know-How arising out of activities conducted by or
on behalf of either Party or jointly by or on behalf of the Parties under the Research Plan, excluding Research Collaboration Data. 
 1.32
“Research Collaboration miRNA” shall mean any miRNA that is identified or discovered in the course and as a result of the Research. 
 1.33 “Research Plan” shall mean the comprehensive plan and budget for Research activities, an initial draft of which is set forth in Schedule A, as updated and approved by mutual
written agreement of the Parties as necessary during the Research Term. 
 1.34 “Research Term” shall mean the first twenty
four (24) months following the Effective Date or such earlier date as all Research activities contemplated by the Research Plan have been completed and the Final Report has been delivered to BI. 

1.35 “Territory” shall mean all the countries of the world. 
 1.36 “Therapeutic Purposes” shall mean the treatment of any disease, disorder or condition in humans. 
 1.37 “Third Party” shall mean any person or entity other than a Party or any of its Affiliates. 
 1.38 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: 

 

					
	     Term
	 	Section	 	 
	
“Agreement”
	 	Introduction	 	 
	
“BI Indemnitees”
	 	10.6.2	 	 
	
“Breaching Party”
	 	9.2.1(a)	 	 
	
“Contact”
	 	3.1	 	 
	
“Existing Licensee Agreement”
	 	1.12	 	 

  
 -5-

					
	
“Final Report”
	 	2.2	 	 
	 “Financial Negotiation
Period”
	 	5.2.2(c)	 	 
	
“Indemnitee”
	 	10.6.3	 	 
	
“Losses”
	 	10.6.1	 	 
	 “Offered
miRNA”
	 	5.2.2(b)	 	 
	 “Offered miRNA
Transaction”
	 	5.2.2(b)	 	 
	 “Negotiation
Period”
	 	5.2.2(c)	 	 
	 “Prohibited
Activities”
	 	5.2.2(c)	 	 
	 “Proposed Term
Sheet”
	 	5.2.2(c)	 	 
	 “Regulus
Indemnitees”
	 	10.6	 	 
	
“Report”
	 	2.2	 	 
	 “Right of First
Negotiation”
	 	5.2.2(b)	 	 

 Article 2 
 COLLABORATION 
 2.1 Research. During the Research Term, Regulus shall perform the
activities under the Research Plan attached hereto as Schedule A and use Commercially Reasonable Efforts to do so on the timelines set forth in the Research Plan. Subject to BI’s compliance with Sections 6.2 and 6.3 hereof, Regulus
shall be solely responsible for paying all costs associated with activities undertaken by it pursuant to the Research Plan, and Regulus shall commit all resources necessary to perform its activities under the Research Plan. Unless Regulus obtains
the prior written consent of BI, solely Regulus, or an Affiliate of Regulus, shall perform its obligations under the Research Plan. BI shall also consult with Regulus in the area of MS in the performance of the Research Plan at its own cost as
reasonably determined by BI in its discretion, and also as described in the Research Plan. 
 2.2 Reports; Research Collaboration Data.
On a quarterly basis during the Research Term, Regulus shall provide a report to BI summarizing the results of the Research conducted, including, without limitation, all Research Collaboration Data, analyses, and statistical calculations used,
as well as the Regulus Collaboration IP developed or Invented in whole or in part by Regulus during the previous quarter (a “Report”), with the first Report to be delivered six (6) months following BI’s first shipment of
Materials, but in no event later than March 31, 2013, and each subsequent Report to be delivered at three-month intervals thereafter. In addition, within sixty (60) days following the completion of the Research activities contemplated by
the Research Plan, Regulus shall provide to BI a final report (the “Final Report”) summarizing the results of the Research conducted and the Regulus Collaboration IP developed or Invented during the Research Term, including, without
limitation, all Research Collaboration Data, and shall confirm to BI with the Final Report that all Research Collaboration Data has been transferred to BI. The Final Report shall be accompanied by samples of the Research Collaboration miRNAs
identified or developed by Regulus under the Research. 
 2.3 Following Completion of the Research. Upon completion of the Research, the
Parties will confer concerning a further collaboration and possible commercialization of a miRNA biomarker assay resulting from the Research. Regulus, or a subsidiary of Regulus approved by BI, will be considered by BI in good faith as a
collaborator to commercialize a miRNA 

  
 -6-

 
biomarker assay for uses such as [...***...]. BI shall not, however, be under any obligation to enter into any such commercial collaboration. 

Article 3 

COLLABORATION COORDINATION 

3.1 Research Coordination. Each of BI and Regulus shall appoint a qualified individual to serve as the primary point of contact for the other Party (the
“Contact”) in all matters related to the Research. Such Contact shall be responsive to the other Party’s reasonable questions and requests and shall facilitate broader discussions between the Parties related to the
Research. The Contact shall be responsible for explaining or supplementing the Report or the Final Report. 
 Article 4

 MATERIAL TRANSFER 
 4.1 Materials. BI shall supply the Materials, as set forth in Exhibit B, to Regulus for evaluation in amounts reasonably necessary for performance of the Research and according to the
Research Plan. The Materials delivered pursuant to this Agreement shall be accompanied by information related to such Materials necessary or useful to the Research Plan, if any. 
 4.2 Ownership. The Materials delivered under this Agreement will remain the sole and exclusive property of BI. Regulus will use the Materials delivered pursuant to this Agreement solely for the
purposes set forth in the Research Plan and not for any other purpose. Regulus will not supply the Materials or any additional materials delivered pursuant to this Agreement to any person not acting pursuant to the Research Plan and will undertake
to use the Materials and any additional materials delivered pursuant to this Agreement in a safe manner and in compliance with all Applicable Laws. 
 4.3 Use. The Materials delivered pursuant to this Agreement will not be used for testing in or treatment of humans, nor used in anything destined for human consumption, nor for any other purpose
inconsistent with the rights specifically granted under this Agreement. 
 4.4 Delivery. BI will provide the supply of Materials within
[...***...] days after the Effective Date. 
 4.5 Return of Leftover Material. At BI’s option, Regulus shall return to BI, at
BI’s cost, or destroy, any leftover Materials remaining at the end of Research Term, and shall provide written certification to BI that it has returned or destroyed all such remaining Material, as the case may be. 

Article 5 

LICENSES AND INTELLECTUAL PROPERTY OWNERSHIP 
 5.1 License Grants to BI. 
 5.1.1 Non-miRNA MS License. Subject to the
terms and conditions of this Agreement, Regulus hereby grants to BI and its Affiliates an exclusive (including with regard to 

  
 -7-

 ***Confidential Treatment Requested 

 
Regulus and its Affiliates), royalty free, fully paid up, irrevocable, worldwide license, with the right to sublicense, under the Regulus Research Collaboration IP and Regulus’s interest in
the Joint Research Collaboration IP to make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and commercialize Non-miRNA Products for the treatment, diagnosis and prevention of MS. 

5.1.2 Non-miRNA Non-MS License. Subject to the terms and conditions of this Agreement, Regulus hereby grants to BI and its
Affiliates an exclusive (including with regard to Regulus and its Affiliates), royalty free, fully paid up, irrevocable, worldwide license, with the right to sublicense, under the Regulus Research Collaboration IP and Regulus’s interest in the
Joint Research Collaboration IP to make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and commercialize Non-miRNA Products for the treatment, diagnosis and prevention of all disease, disorders or conditions
in humans and animals other than MS. 
 5.1.3 miRNA Diagnostic MS License. Subject to the terms and conditions of this
Agreement, Regulus hereby grants to BI and its Affiliates (i) an exclusive (including with regard to Regulus and its Affiliates), royalty free, fully paid up, irrevocable, worldwide license, with the right to sublicense, under the Regulus
Research Collaboration IP and Regulus’s interest in the Joint Research Collaboration IP to make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and commercialize miRNA Products for the diagnosis of MS and
(ii) a non-exclusive royalty free, fully paid up, irrevocable, worldwide license, with the right to sublicense, under the Regulus Background IP to make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and
commercialize miRNA Products for the diagnosis of MS. Notwithstanding the foregoing, the license granted to BI pursuant to clause (ii) of this Section shall not include any Regulus Background IP to the extent that BI’s exercise of the
rights granted pursuant to this Section would result in a payment obligation by Regulus to any Third Party licensor of such Regulus Background IP, unless BI agrees to make such payments to Regulus (which payments, for the avoidance of doubt, shall
only include the incremental payments that are owed to any such Third Party as a result of BI’s exercise of its rights under such clause (ii), without any additional payments to Regulus) on terms reasonably acceptable to both Parties.
Regulus shall use Commercially Reasonable Efforts to obtain for BI the right under any agreements with Third Parties entered into by Regulus prior to or during the Agreement Term to enjoy such non-exclusive license as set forth in clause
(ii) above for those licenses with respect to which BI agrees to reimburse Regulus for any out of pocket costs paid by Regulus for such non-exclusive license rights, but no additional costs or profits shall be payable by BI in connection
therewith . Regulus shall advise BI of any such payments obligations and discuss in good faith with BI such payment terms described in this Section. For the avoidance of doubt, this Section 5.1.3 shall not be construed as obligating Regulus to
seek or obtain any license under any Third Party intellectual property rights. 
 5.2 License Grants to Regulus. 

5.2.1 Research License. Subject to the terms and conditions of this Agreement, BI hereby grants to Regulus during the Research Term
a non-exclusive, fully-paid up, 

  
 -8-

 
irrevocable, royalty-free, worldwide license to all Know-How and Patent Rights Controlled by BI during the Research Term that are necessary or useful for Regulus to perform activities under the
Research Plan for the sole purpose of enabling Regulus to perform activities under the Research Plan, including, without limitation, use of the Materials. 
 5.2.2 miRNA Therapeutic License; Restrictions on Development and Commercialization of Therapeutic miRNA Products. 
 (a) Subject to the terms and conditions of this Agreement, including, without limitation, this Section 5.2.2, BI hereby grants to Regulus and its Affiliates an exclusive (including with regard to BI
and its Affiliates), royalty free, fully paid up, irrevocable, worldwide license, with the right to sublicense, under the BI Research Collaboration IP, BI’s interest in the Joint Research Collaboration IP and the Research Collaboration Data, to
make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and commercialize miRNA Products for Therapeutic Purposes. 
 (b) On a miRNA Product by miRNA Product basis, in the event that Regulus or any of its Affiliates intends, directly or indirectly, to enter into any license, covenant not to sue, co-development,
co-commercialization, co-promotion or any other arrangement pursuant to which Regulus would grant to any Third Party any rights, or any option with respect to any such rights, to such miRNA Product that include Therapeutic Purposes (the
“Offered miRNA”), including any amendment to any existing agreement to which Regulus is a party which amendment adds any Offered miRNA to the scope of any such existing agreement or increases the ability of the other party to such
agreement to obtain rights to such Offered miRNA but excluding a grant of rights to a Third Party solely to perform activities on Regulus’s behalf (an “Offered miRNA Transaction”), BI shall have the rights with respect to such
Offered miRNA set forth in this Section 5.2.3(the “Right of First Negotiation”). 
 (c) Prior to entering
into any discussions, negotiations, solicitations of interest or other interaction with any Third Party regarding an Offered miRNA Transaction (the “Prohibited Activities”) or entering into any Offered miRNA Transaction, Regulus
shall provide to BI provide a reasonably detailed term sheet identifying the Offered miRNA and the proposed terms of the Offered miRNA Transaction, including all financial terms (the “Proposed Term Sheet”). Unless BI notifies
Regulus at any time that it does not wish to continue negotiations, BI and Regulus will negotiate in good faith the financial terms of the Offered miRNA Transaction for a period of [...***...] days, or such period as otherwise agreed by the Parties,
from the date that BI receives (i) the Proposed Term Sheet and (ii) all relevant scientific data for the Offered miRNAs identified in the Proposed Term Sheet, and any other data that BI may reasonably request (the “Financial
Negotiation Period”). Regulus may not engage in any Prohibited Activities regarding the applicable Offered miRNA during the Financial Negotiation Period. If BI and Regulus reach agreement during the Financial

  
 -9-

 ***Confidential Treatment Requested 

 
Negotiation Period on financial terms regarding the Offered miRNA Transaction BI that are, taken as a whole, equal to or better than the financial terms contained in the Proposed Term Sheet, then
BI and Regulus shall negotiate in good faith the terms of the Offered miRNA Transaction for a period of [...***...] months, or such period as otherwise agreed by the Parties, plus any portion of the Financial Negotiation Period that has not
expired prior to the Parties reaching agreement on such financial terms (the “Negotiation Period”), during which period Regulus may not engage in any Prohibited Activities regarding the applicable Offered miRNA. 

(d) With respect to a particular Proposed Term Sheet, in the event that (i) BI and Regulus do not reach agreement on financial
terms during the Financial Negotiation Period that are, taken as a whole, equal to or better than the financial terms contained in the Proposed Term Sheet, (ii) BI notifies Regulus prior to the end of the Financial Negotiation Period that it
does not intend to negotiate the terms of an applicable Proposed Term Sheet or (iii) BI and Regulus are unable, despite the use of good faith efforts to reach agreement on the terms of an Offered miRNA Transaction during the Negotiation Period,
then Regulus shall be free, for a period of [...***...] months from the expiration of the Financial Negotiation Period, in the case of clause (i) of this Section 5.2.2(d), the date that BI notifies Regulus that it does not intend to
negotiate the terms contained in the Proposed Term Sheet, in the case of clause (ii) of this Section 5.2.2(d), or the expiration of the Negotiation Period, in the case of clause (iii) of this Section 5.2.2(d), to enter into
negotiations with any Third Party to conclude an Offered miRNA Transaction solely with respect to the Offered miRNA identified in the applicable Proposed Term Sheet; provided that, any such transaction entered into with a Third Party must be on
financial terms that are, taken as a whole, greater than those contained in the Proposed Term Sheet, in the case of clause (i) or (ii) of this Section 5.2.2(d), or greater than those contained in the last written counter proposal
provided by BI in the course of negotiations in the case of clause (iii) of this Section 5.2.2(d). In the event that Regulus enters into an Offered miRNA Transaction with a Third Party pursuant to the preceding sentence, the Chief
Executive Officer of Regulus will certify in writing to BI that the Regulus Board of Directors has reviewed the Offered miRNA Transaction in light of the obligations contained in this Section 5.2.2, and that the Board has concluded that such
Offered miRNA Transaction is financially better for Regulus than the Proposed Term Sheet or last BI counter proposal, as applicable, it being understood that the delivery of such certification shall in no way limit any rights of remedies available
to BI as a result of any breach by Regulus of this Section 5.2.2. In the event that Regulus does not enter into an Offered miRNA Transaction with a Third Party pursuant to this Section 5.2.2(d) within the applicable time period described
in this Section 5.2.2(d), Regulus may not thereafter enter into an Offered miRNA Transaction with respect to the applicable Offered miRNA without offering BI a Right of First Negotiation in compliance with this Section 5.2.2. 

  
 -10-

 ***Confidential Treatment Requested 

 (e) The Right of First Negotiation set forth in this Section 5.2.2 shall be subject to
the following additional terms and limitations: 
 (i) The Right of First Negotiation shall not apply to miRNA Products that
have been licensed to any Existing Licensee under an Existing Licensee Agreement under the terms of any such agreement as it exists on the Effective Date or is first entered into following the Effective Date, except that the Right of First
Negotiation shall apply to any such miRNA Product that may subsequently cease to be licensed to any such Existing Licensee. Regulus shall promptly notify BI if any miRNA Product is not subject to the Right of First Negotiation pursuant to this
clause (i), whether at the time that the applicable miRNA is first identified pursuant to this Agreement or at any time following such identification, and if any such miRNA Product subsequently becomes subject to the Right of First Negotiation.

 (ii) The Right of First Negotiation shall not apply to any miRNA Product after the [...***...] anniversary of the
expiration of Research Term, except that the terms of Section 5.2.2 shall continue to apply to any miRNA Product with respect to which Regulus has delivered a Proposed Term Sheet to BI prior to such fifth anniversary. 

5.3 Ownership of and Rights to Intellectual Property. 
 5.3.1 Disclosure. Each Party agrees promptly to disclose to the other Party all Research Collaboration IP made by or under authority of such Party under this Agreement during the Research Term.

 5.3.2 Data. Regulus will provide all Research Collaboration Data to BI in the form in which such data was gathered. BI
shall own all Research Collaboration Data. 
 5.3.3 Joint IP. Subject to the licenses granted in this Agreement, the
Parties shall own the Joint Research Collaboration IP jointly. Subject to the obligations each Party has under this Agreement, neither Party shall have any obligation to account to the other for profits, or to obtain any approval of the other Party
to license, assign or otherwise exploit such Party’s interest in, the Joint Research Collaboration IP, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any
such approval or accounting. 
 5.3.4 BI Research Collaboration IP ; Research Collaboration Data. Subject to the licenses
granted in this Agreement, BI is and shall remain the sole owner of the BI Research Collaboration IP and the Research Collaboration Data. 
 5.3.5 Regulus Research Collaboration IP. Subject to the licenses granted in this Agreement, Regulus is and shall remain the sole owner of the Regulus Research Collaboration IP. 

  
 -11-

 ***Confidential Treatment Requested 

 5.3.6 Further Assurances. Regulus hereby assigns all rights, title, and interest it
has in any Research Collaboration Data to BI, and both Parties agree in connection herewith to take all actions reasonably requested by the other Party to effectuate the grant of rights herein provided, including the assignment of Research
Collaboration Data. 
 5.3.7 Disputes as to Inventorship of Research Collaboration IP. Should the Parties fail to agree
regarding Inventorship of any invention made in the conduct of activities under the Research Plan or the ownership of Research Collaboration IP arising out of this Agreement, patentable or not-patentable, the Parties shall refer the matter to a
mutually agreed-upon outside counsel for resolution. All determinations of inventive contribution for inventions arising hereunder shall be determined under United States patent law. The costs of such outside counsel shall be borne equally by the
Parties. 
 5.4 No Other Rights. Except as otherwise provided in this Agreement, neither Party shall obtain any ownership
interest or other right in any Know-How or Patent Rights owned or Controlled by the other Party. 
 Article 6 

FINANCIAL PROVISIONS 
 6.1
Research Term Expenses. Each Party shall bear the expenses associated with its performance under the Research Plan. 
 6.2
Collaboration Fee. Within ten (10) days after the Effective Date, BI shall pay to Regulus a one-time collaboration fee of Seven Hundred and Fifty Thousand Dollars ($750,000). 
 6.3 Milestones. BI shall also pay to Regulus the amounts set forth below no later than forty-five (45) days after the date on which Regulus notifies BI that the corresponding milestone event
as described in the Research Plan has first been achieved and after such achievement is confirmed by BI in its reasonable discretion: 
  

			
	 Milestone Event
	 	Payment
	 	 	 
	 	 	 
	
[...***...]
	 	$[...***...]
	
[...***...]
	 	$[...***...]
	
[...***...]
	 	$[...***...]

  
 -12-

 ***Confidential Treatment Requested 

 6.4 Payment Provisions Generally. 

6.4.1 Taxes and Withholding. If laws, rules or regulations require withholding of income taxes, other taxes or related interest or
penalties thereon, imposed upon such payments set forth in Section 6, BI shall make such withholding payments as required and subtract such withholding payments from the payments set forth in Section 6. BI shall submit
appropriate proof of payment of the withholding taxes to Regulus within a reasonable period of time. At the request of Regulus, BI shall, at Regulus’s cost, give Regulus such reasonable assistance, which shall include the provision of
appropriate certificates of such deductions made together with other supporting documentation as may be required by the relevant tax authority, to enable Regulus to claim exemption from such withholding or other tax imposed or obtain a repayment
thereof or reduction thereof and shall upon request provide such additional documentation from time to time as is reasonably required to confirm the payment of tax. 
 6.4.2 Payment. All amounts payable and calculations hereunder shall be in United States dollars and shall be paid by bank wire transfer in immediately available funds to such bank account in the
United States as may be designated in writing by Regulus from time to time. 
 6.4.3 Overdue Payments. If any payment due
by BI to Regulus under this Agreement (other than payments that are the subject of a good faith dispute between the Parties) is overdue by more than ten (10) days, BI shall pay interest to Regulus at a rate per annum equal to the lesser of
(i) the [...***...] percent
 ([...***...]%) as reported by [...***...] on the date such payment is due, or (ii) the highest rate permitted by applicable law, calculated on the number of days such payments are paid
after the date such payments are due. 
 Article 7 
 INTELLECTUAL PROPERTY PROTECTION AND RELATED MATTERS 
 7.1 Filing, Prosecution,
Maintenance and Enforcement of Patent Rights. 
 7.1.1 Regulus Patent Rights. 

(a) Regulus, through counsel of its choosing and at its sole expense, shall have sole responsibility for and control over obtaining,
prosecuting (including any interferences, reissue proceedings, re-examinations, and patent adjustments and restorations), maintaining and enforcing throughout the Territory the Patent Rights included in or covering Regulus Background IP and, subject
to Section 7.1.1(b), Regulus Research Collaboration IP. For the avoidance of doubt, and notwithstanding any other provision of this Agreement to the contrary, Regulus shall have the right to disclose Research Collaboration Data in patent
applications in support of claims covering Regulus Research Collaboration IP; provided that, prior to disclosing any Research Collaboration Data in any such patent applications, Regulus first shall provide to BI a copy of any such patent application
reasonably in advance of the date it intends to file such patent 

  
 -13-

 ***Confidential Treatment Requested 

 
application and removes from such patent application any Research Collaboration Data included in such patent application requested by BI in its discretion. Prior to or contemporaneous with making
such request BI shall discuss the request with Regulus and the explanation for the removal of such Data. 
 (b) If Regulus
elects (i) not to file and prosecute patent applications for any Patent Rights included in or covering the Regulus Research Collaboration IP in any country, (ii) not to continue the prosecution (including any interferences, oppositions,
reissue proceedings, re-examinations, and patent adjustments and restorations) or maintenance of any such Patent Rights in a particular country in the Territory, or (iii) not to file and prosecute patent applications covering any Regulus
Research Collaboration IP following a written request from BI to file and prosecute in such country, then Regulus shall so notify BI promptly in writing of its intention, which notice shall, in any event, be given no later than 60 days prior to
the next deadline for any action that must be taken with respect to such patent application or patent to establish or preserve any such rights in such patent application or patent in such country. Regulus shall cooperate with and permit BI, should
BI choose to do so, to file for, or continue to prosecute, maintain or enforce, or otherwise pursue such Patent Rights in such country in Regulus’s name at BI’s sole expense. 

7.1.2 BI Patent Rights. 
 (a) Except as set forth in Section 7.1.2(b), BI, through counsel of its choosing and at its sole expense, shall have sole responsibility for and control over obtaining, prosecuting (including any
interferences, reissue proceedings, re-examinations, and patent adjustments and restorations), maintaining and enforcing throughout the Territory the Patent Rights included in or covering BI Research Collaboration IP.  

(b) If BI elects (i) not to file and prosecute patent applications for any Patent Rights included in or covering the BI Research
Collaboration IP in any country, (ii) not to continue the prosecution (including any interferences, oppositions, reissue proceedings, re-examinations, and patent adjustments and restorations) or maintenance of any such Patent Rights in a
particular country in the Territory, or (iii) not to file and prosecute patent applications covering any BI Research Collaboration IP following a written request from Regulus to file and prosecute in such country, then BI shall so notify
Regulus promptly in writing of its intention, which notice shall, in any event, be given no later than 60 days prior to the next deadline for any action that must be taken with respect to such patent application or patent to establish or
preserve any such rights in such patent application or patent in such country. BI shall cooperate with and permit Regulus, should Regulus choose to do so, to file for, or continue to prosecute, maintain or enforce, or otherwise pursue such Patent
Rights in such country in BI’s name at Regulus’s sole expense. 

  
 -14-

 7.1.3 Joint Patent Rights. 

(a) Primary Responsibility. Unless otherwise agreed by the Parties on a case-by-case basis, BI, through counsel of its choosing,
shall have primary responsibility for and control over obtaining, prosecuting (including any interferences, reissue proceedings, re-examinations, and patent term extensions, adjustments, and restorations), and maintaining throughout the Territory
all Patent Rights included in or covering Joint Research Collaboration IP. BI shall consult with Regulus as to the preparation, filing, prosecution and maintenance of such Patent Rights reasonably prior to any deadline or action with any patent
office, and shall furnish to Regulus copies of all relevant documents reasonably in advance of such consultation. BI shall reasonably consider all comments and suggestions of Regulus. All out of pocket expenses of such activities under this
Section 7.1.3(a) shall be borne equally by the Parties, and Regulus shall promptly reimburse BI for out of pocket expenses incurred by BI in such activities upon receipt of an invoice by BI for Regulus’s share of such out of pocket
expenses. Regulus may cease reimbursing patent costs and expenses with respect to any such Patent Rights, in their entirety or on a country by country basis, upon written notice to BI, whereupon Regulus shall cease to have any license hereunder with
respect to the applicable Patent Right and shall assign to BI its joint ownership interest therein in the applicable country or countries, provided that Regulus shall remain responsible for reimbursement of patent costs and expenses with respect to
such BI Patent or Joint Patent for a period of 60 days after delivery of such written notice to BI. 
 (b) Election not
to Continue Prosecution; Abandonment. If BI elects (a) not to file and prosecute patent applications for any Patent Rights included in or covering Joint Research Collaboration IP in any country, (b) not to continue the prosecution
(including any interferences, oppositions, reissue proceedings, re-examinations, and patent term extensions, adjustments, and restorations) or maintenance of such Patent Rights in a particular country in the Territory, or (c) not to file and
prosecute patent applications for such Patent Rights in a particular country following a written request from Regulus to file and prosecute in such country, which election may be made by BI in its discretion, then BI shall so notify Regulus promptly
in writing of its intention, which notice shall, in any event, be given no later than 60 days prior to the next deadline for any action that must be taken with respect to such patent application or patent to establish or preserve any such
rights in such patent application or patent in such country, BI shall assign to Regulus its joint ownership interest in such Patent Rights in the applicable country or countries and shall cooperate with and permit Regulus, should Regulus choose to
do so, to file for, or continue to prosecute, maintain or enforce, or otherwise pursue such Patent Rights in such country in Regulus’s own name, but only to the extent that Regulus does not take any position with respect to such abandoned
Patent Right that would be reasonably likely to adversely affect the scope, validity or enforceability of any of the other Patent Rights being prosecuted and maintained by BI under this Agreement without the prior written consent of BI, which
consent shall not be unreasonably withheld. To the extent 

  
 -15-

 
permitted by this Section, if Regulus chooses to file, continue to prosecute, maintain or enforce, or otherwise pursue such Patent Rights, it shall keep BI fully informed of the patent
prosecution, and provide BI with copies of material correspondence relating to the prosecution and maintenance of such Patent Rights in a timely manner so that BI can comment thereon. Regulus shall reasonably consider all such comments. 

7.1.4 Cooperation. Each Party hereby agrees: (a) to make its employees, agents and consultants reasonably available to the
other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake patent prosecution as contemplated by this Agreement; (b) to cooperate, if
necessary and appropriate, with the other Party in gaining patent term extensions wherever applicable to Patent Rights that are subject to this Agreement; and (c) to endeavor in good faith to coordinate its efforts with the other Party to
minimize or avoid interference with the prosecution and maintenance of the other Party’s patent applications that are subject to this Agreement. 
 7.2 Enforcement of Patent Rights. 
 7.2.1 Notification. Each Party
shall promptly report in writing to the other Party during the Agreement Term any (a) known or suspected infringement of any Patent Rights included in or covering Research Collaboration IP or (b) unauthorized use or misappropriation of any
Confidential Information by a Third Party of which it becomes aware, and shall provide the other Party with all available evidence supporting such infringement, or unauthorized use or misappropriation. 

7.2.2 Enforcement. 
 (a) Except as otherwise may be agreed between the Parties pursuant to any agreement entered into between the Parties pursuant to Section 5.2.2, BI shall have the sole right, but not the obligation,
to bring and control any action or proceeding against a Third Party with respect to infringement of: (i) any Patent Rights included in or covering BI Research Collaboration IP, except with respect to any infringing activity involving a product
employing, based on, utilizing or comprising any one or more MicroRNAs for Therapeutic Purposes; and (ii) any Patent Rights included in or covering Joint Collaboration IP with respect to any infringing activity involving a product (other than a
product employing, based on, utilizing or comprising any one or more miRNAs for Therapeutic Purposes) that is competitive with any Non-miRNA Product being developed by or on behalf of BI; in each case, at its sole cost and expense and by counsel of
its own choice. With respect to infringing activity involving a product employing, based on, utilizing or comprising any one or more MicroRNAs for Therapeutic Purposes with respect to which Regulus chooses to bring an action pursuant to this
Agreement, Regulus shall keep BI and its counsel reasonably informed regarding the status and activities of such action and shall reasonably consider BI’s suggestions in connection therewith. 

  
 -16-

 (b) Except as otherwise may be agreed between the Parties pursuant to any agreement entered
into between the Parties pursuant to Section 5.2.2, BI shall have the first right, but not the obligation, to bring and control any action or proceeding against a Third Party with respect to infringement of, any Patent Rights included in or
covering Regulus Research Collaboration IP with respect to any infringing activity involving a product (other than a product employing, based on, utilizing or comprising any one or more MicroRNAs for Therapeutic Purposes) that is competitive with
any Non-miRNA Product being developed by or on behalf of BI, at its sole cost and expense and by counsel of its own choice, and Regulus shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If
BI fails to bring any such action or proceeding within (1) 120 days following the notice of alleged infringement, or (2) 30 days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of
such actions, whichever comes first, then Regulus shall have the right to bring and control any such action, at its own expense and by counsel of its own choice, and BI shall have the right, at its own expense, to be represented in any such action
by counsel of its own choice. In the event Regulus brings an action against an infringer pursuant to this Section, Regulus shall keep BI and its counsel reasonably informed regarding the status and activities of such action and shall reasonably
consider BI’s suggestions in connection therewith. 
 (c) Regulus shall have the sole right, but not the obligation, to
bring and control any action or proceeding against a Third Party with respect to infringement of: (i) any Patent Rights included in or covering Regulus Background IP; (ii) any Patent Rights included in or covering Regulus Collaboration IP
with respect to any infringing activity involving a product employing, based on, utilizing or comprising any one or more MicroRNAs (other than a product employing, based on, utilizing or comprising any one or more MicroRNAs for the diagnosis of MS,
with respect to which BI shall have the right, but not the obligation to bring such action or proceeding); and (iii) any Patent Rights included in or covering Joint Collaboration IP with respect to any infringing activity involving a product
employing, based on, utilizing or comprising any one or more MicroRNAs that is competitive with any miRNA Product being developed by or on behalf of Regulus; in each case, at its sole cost and expense and by counsel of its own choice. 

(d) Regulus shall have the first right, but not the obligation, to bring and control any action or proceeding against a Third Party with
respect to infringement of, any Patent Rights included in or covering BI Research Collaboration IP with respect to any infringing activity involving a product employing, based on, utilizing or comprising any one or more MicroRNAs that is competitive
with any miRNA Product being developed by or on behalf of Regulus, at its sole cost and expense and by counsel of its own choice, and BI shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If
Regulus fails to bring any such action or proceeding within (1) 120 days following the notice of alleged infringement, or (2) 30 days before the time limit, if any, set forth in the appropriate laws and regulations for

  
 -17-

 
the filing of such actions, whichever comes first, then BI shall have the right to bring and control any such action, at its own expense and by counsel of its own choice, and Regulus shall have
the right, at its own expense, to be represented in any such action by counsel of its own choice. 
 (e) In the case of
infringement of any Patent Rights included in or covering Joint Collaboration IP that has not been assigned to a Party as the sole owner thereof in accordance with this Agreement, other than infringing activity described in clause (ii) of
Section 7.2.2(a) or clause (iii) of Section 7.2.2(c), the Parties shall mutually agree on a case-by-case basis which of them will take the lead in enforcing such Patent Rights. 

7.2.3 Procedures; Expenses and Recoveries. If required under applicable law in order for a Party that has the right to do so
hereunder to initiate and/or maintain a suit against an infringer or misappropriater of Research Collaboration IP, or if it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party shall join as a party to the suit
and shall execute and cause its Affiliates to execute all documents necessary for such Party to initiate litigation to prosecute and maintain such action. In addition, at an initiating Party’s request, the other Party shall provide reasonable
assistance to the initiating Party in connection with an infringement suit at no charge to the initiating Party except for reimbursement by the initiating Party of reasonable out-of-pocket expenses incurred in rendering such assistance. If the
Parties obtain from a Third Party, in connection with such suit, any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation), such amounts shall be allocated to reimburse each Party for
all expenses of the suit, including attorneys’ fees and disbursements, court costs and other litigation expenses. Any remaining amount will be retained by the Party initiating such suit; provided, however, that, except as otherwise
agreed by the Parties as part of a cost-sharing arrangement, any amount recovered by either Party pursuant to Section 7.2.2(e) shall be shared by the Parties on a fifty-fifty (50/50) basis. 

7.3 Other Infringement Resolutions. In the event of a dispute or potential dispute that has not ripened into a demand, claim or
suit of the types described in Section 7.2. of this Agreement (e.g., actions seeking declaratory judgments and revocation proceedings), the same principles governing control of the resolution of the dispute, consent to settlements
of the dispute, and implementation of the settlement of the dispute (including allocating the payment or receipt of damages, license fees, royalties and other compensation) shall apply. 

7.4 Common Interest. All information exchanged between the parties or between outside patent counsel for each with the other party
regarding preparation, filing, prosecution, maintenance, or enforcement of Patent Rights hereunder shall be deemed Confidential Information. In addition, the Parties acknowledge and agree that, with regard to such preparation, filing, prosecution,
maintenance, and enforcement of the Patent Rights hereunder, the interests of the Parties as licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and
acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal 

  
 -18-

 
privilege concerning the Patent Rights hereunder, including without limitation, privilege under the common interest doctrine and similar or related doctrines. 

Article 8 

CONFIDENTIALITY 
 8.1
Confidential Information. 
 8.1.1 Confidentiality. All Confidential Information disclosed by a Party to the other
Party during the Agreement Term shall be used by the receiving Party solely in connection with the activities contemplated by this Agreement, shall be maintained in confidence by the receiving Party and shall not otherwise be disclosed by the
receiving Party to any other person, firm, or agency, governmental or private (other than a Party’s Affiliates), without the prior written consent of the disclosing Party except in connection with the activities contemplated by this Agreement.
Regulus and BI each agree that they shall provide Confidential Information received from the other Party only to their respective employees, consultants and advisors, and to the employees, consultants and advisors of such Party’s Affiliates,
and Third Parties acting on behalf of the Parties, who have a need to know and have an obligation to treat such information and materials as confidential. All obligations of confidentiality imposed under this Article 8 shall expire ten
(10) years following termination or expiration of this Agreement. 
 8.1.2 Authorized Disclosure. Notwithstanding
the provisions of Section 8.1, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(a) complying with Applicable Laws or with applicable court orders; 

(b) filing or prosecuting patent applications as contemplated by this Agreement; 

(c) defending or prosecuting litigation, provided that the receiving Party provides prior notice of such disclosure to the
disclosing Party and takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure; 
 (d) making
filings and submissions to, or corresponding or communicating with, any Regulatory Authority or clinical registry, including without limitation for purposes of obtaining authorizations to conduct clinical trials of, and to market and sell, products
pursuant to this Agreement; 
 (e) exercising its rights hereunder, provided such disclosure is covered by terms of
confidentiality similar to those set forth herein; 
 (f) enforcing its rights hereunder; and 

(g) disclosure to Third Parties in connection with due diligence by such Third Parties, and disclosure to potential Third Party
investors in confidential financing 

  
 -19-

 
documents; provided, however, that, in each case, any such Third Party agrees to be bound by written obligations of confidentiality and non-use no less strict than the terms of this
Agreement; and provided, further, that disclosure of any Research Collaboration Data by Regulus to any Third Party pursuant to this Section 8.1.2(g) will require the prior written consent of BI, and BI shall in good faith consider any
request by Regulus to allow Regulus to provide Research Collaboration Data to a Third Party pursuant to this Section 8.1.2(g) for reasonable business purposes. If BI consents to disclosure of specific Research Collaboration Data by Regulus to
any Third Party pursuant to this Section 8.1.2(g), Regulus shall have the right to disclose such Research Collaboration Data to other Third Parties pursuant to this Section 8.1.2(g), subject to written obligations of confidentiality and
non-use no less strict than the terms of this Agreement. 
 In the event a Party shall deem it reasonably necessary to disclose
Confidential Information belonging to the other Party pursuant to clause (a) or clause (c) of this Section 8.1.2, such Party shall to the extent possible give reasonable advance notice of such disclosure to the other Party and
take reasonable measures to obtain confidential treatment of such information if available. 
 8.1.3 Confidentiality of
Agreement. This Agreement, including its terms and subject matter, shall be deemed the Confidential Information of both Parties. 
 8.2
Publication Review. Each Party shall provide to the other Party for information and review any abstracts, posters and slide presentations prior to any scientific meetings, and primary and final manuscripts, and review articles prior to
journal submission in each case to the extent related to the Research or the Research Collaboration IP, and the other Party shall have up to thirty (30) days to provide feedback. The Party proposing such publication shall remove any
Confidential Information of the other Party identified by the other Party and shall delay such publication for up to an additional sixty (60) days to permit the other Party to file for patent protection to protect any Research Collaboration IP
of the other Party included in such proposed publication and shall reasonably consider all other comments of the other Party. Expedited reviews for abstracts or poster presentations may be arranged if mutually agreeable to the Parties. The other
Party may also require that its Confidential Information that may be disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. 

Article 9 

TERM AND TERMINATION 
 9.1
Term. The Agreement Term shall commence on the Effective Date and shall continue until terminated by mutual agreement of the Parties or otherwise terminated in accordance with this Article 9. 

9.2 Termination for Cause.  
 9.2.1 Cause for Termination. This Agreement may be terminated at any time during the Agreement Term: 

  
 -20-

 (a) upon notice by either Party if the other Party (the “Breaching Party”)
is in material breach of its obligations hereunder and has not cured such breach within sixty (60) days after notice requesting cure of the breach. Without limitation, any uncured breach of the Note (as defined herein) by Regulus shall be
deemed a breach of this Agreement (and the time frames for cure herein shall not apply); or 
 (b) by either Party upon the
filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the
event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days
after the filing thereof. 
 9.2.2 Effect of Termination for Cause. 

(a) Termination by Regulus. Without limiting any other legal or equitable remedies that Regulus may have, if BI is the Breaching
Party and Regulus terminates this Agreement in accordance with Section 9.2.1(a), then (i) all licenses granted by BI to Regulus shall remain in effect, (ii) BI will have no continuing rights to exercise the Right of First
Negotiation, (iii) all licenses granted by Regulus to BI shall terminate and (iv) BI will assign to Regulus all of its rights in the Research Collaboration Data. 
 (b) Termination by BI. Without limiting any other legal or equitable remedies that BI may have, if Regulus is the Breaching Party and BI terminates this Agreement in accordance with
Section 9.2.1(a), then (i) all licenses granted by Regulus to BI shall remain in effect, (ii) all licenses granted by BI to Regulus shall terminate, (iii) all Materials shall be returned in accordance with
Section 4.5, and Regulus shall, and shall hereby be deemed to, grant to BI and its Affiliates an exclusive (including with regard to Regulus and its Affiliates), royalty free, fully paid up, irrevocable, worldwide license, with the right to
sublicense, under the Regulus Research Collaboration IP and Regulus’s interest in the Joint Research Collaboration IP to make, have made, use, offer to sell, sell, have sold, import, export, and otherwise develop and commercialize miRNA
Products for the treatment of MS, (iv) Regulus will transfer to BI all rights in all miRNA Products being developed or commercialized for the treatment of MS at such time, (v) if such termination occurs prior to the end of the Research
Term, at BI’s election, and subject to BI’s compliance with its payment obligations under Section 6.3, Regulus will continue to complete the activities under the Research Plan and provide all reports and materials to BI concerning
such activities as required by this Agreement, (vi) the Note will, at BI’s election, immediately become due and payable, (vii) Regulus shall use Commercially Reasonable Efforts to obtain a non-exclusive, sublicensable, worldwide
license to any Regulus Background IP necessary or useful to allow BI to enjoy the rights granted in this Section 9.2.2(b), 

  
 -21-

 
and subject to the terms in 5.1.3 and (viii) the provisions of Section 5.2.2 shall survive such termination until its natural expiration set forth in 5.2.2(e)(ii). 

9.3 Termination for Convenience. Either Party may terminate this Agreement in its entirety, for any reason, upon thirty (30) days’
advance notice to the other Party. If this Agreement is terminated pursuant to this Section 9.3, then such termination shall have the effect set forth in Section 9.2.2(a) if BI is the terminating Party and 9.2.2(b) if Regulus is the
terminating Party; in addition, if Regulus is the terminating Party, BI shall be entitled to receive all unexpended funds paid to Regulus. 

9.4 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement, including without limitation
Section 4.5, are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, licenses of right to “intellectual
property” as defined under Section 101 of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter “IP”). The Parties agree that each Party, as licensee of such rights under
this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that provide similar protection for IP. Each Party hereby grants
to the other Party and its Affiliates a right to obtain possession of and to benefit from a complete duplicate of (or complete access to, as appropriate) any such IP and all embodiments of intellectual property, which, if not already in the other
Party’s possession, shall be promptly delivered to it upon the other Party’s written request therefor. The term “embodiments of intellectual property” includes all tangible, electronic or other embodiments of rights and licenses
hereunder. Neither Party shall interfere with the exercise by the other Party or its Affiliates of rights and licenses to IP and embodiments of intellectual property licensed hereunder in accordance with this Agreement and agrees to assist the other
Party and its Affiliates to obtain the IP and embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for the other Party or Affiliates of BI to exercise such rights and licenses in
accordance with this Agreement. 
 9.5 Effect of Expiration or Termination; Survival. 

9.5.1 Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. The provisions of Articles 1, 4.2, 4.3, 4.5, 5.3.3, 7.1.3, 7.1.4, 8, 9, 10 and 11, and those provisions which, by the terms of the applicable Article 9 Termination provision, should also survive, shall survive any expiration or
termination of this Agreement. Except as set forth in this Article 9, upon termination or expiration of this Agreement all other rights and obligations cease. Any expiration or early termination of this Agreement shall be without prejudice to the
rights of either Party against the other accrued or accruing under this Agreement before termination. 

  
 -22-

 Article 10 
 REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 
 10.1 Mutual Representations and
Warranties. Each Party represents and warrants to the other Party that as of the Effective Date of this Agreement: 
 10.1.1
It is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof. Further, all
necessary consents, approvals and authorizations of all government authorities required to be obtained by such Party as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained by the
Effective Date. 
 10.1.2 It is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder,
and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action. 
 10.1.3 This Agreement is legally binding upon it and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party and by which it may be bound, including any Existing Licensee Agreement. 
 10.1.4 Each employee or representative of such Party or any Third Party working in collaboration with such Party that performs Research hereunder has covenanted to assign to such Party all of its future
interest in any technology that would otherwise constitute Research Collaboration IP. 
 10.2 Regulus Covenants, Representations and
Warranties. Regulus represents and warrants to BI that, as of the Effective Date of this Agreement (except with respect to the representation set forth in Section 10.2.3, which shall be made as of the Effective Date and as of each date
thereafter that Schedule C is required to be updated pursuant to the terms hereof) and agrees with BI: 
 10.2.1 Regulus has not
previously assigned, transferred, licensed, conveyed or otherwise encumbered its right, title and interest in the Regulus Background IP in a manner that conflicts with any rights granted to BI hereunder. During the Agreement Term, Regulus shall not
encumber the rights granted to BI hereunder with respect to the Regulus Research Collaboration IP or the Regulus Background IP. 

10.2.2 To the best knowledge of Regulus and its Affiliates, there are no claims, judgments or settlements against or owed by Regulus or
its Affiliates or pending or threatened claims or litigation relating to the Regulus Background IP that are expected to impact the activities to be performed by Regulus in the Research. 

10.2.3 No Existing Licensee has, or has a right to obtain, a license under an Existing Licensee Agreement to more than four
(4) miRNAs targets. 

  
 -23-

 10.3 BI Covenants, Representations and Warranties. Regulus represents and warrants to BI that as of
the Effective Date of this Agreement: 
 10.3.1 During the Agreement Term, BI shall not encumber the rights granted to Regulus
hereunder with respect to the BI Research Collaboration IP or the Joint Research Collaboration IP. 
 10.3.2 To the best
knowledge of BI and its Affiliates, there are no claims, judgments or settlements against or owed by BI or its Affiliates or pending or threatened claims or litigation relating to the Materials that are expected to impact the activities to be
performed by Regulus in the Research. 
 10.4 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY MATERIALS, TECHNOLOGY OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT
UNDER THIS AGREEMENT SHALL BE SUCCESSFUL. 
 10.5 No Consequential Damages. NEITHER PARTY HERETO SHALL BE LIABLE FOR SPECIAL, INCIDENTAL,
INDIRECT, AND/OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH
DAMAGES. NOTHING IN THIS SECTION 10.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY OR TO LIMIT A PARTY’S LIABILITY FOR BREACHES OF ITS OBLIGATION REGARDING CONFIDENTIALITY UNDER ARTICLE
8. 
 10.6 Indemnification and Insurance. 
 10.6.1 Indemnification by BI. BI shall indemnify, hold harmless, and defend Regulus, its Affiliates, and their respective directors, officers, medical and professional staff, employees and agents
and their respective successors, heirs and assigns (“Regulus Indemnitees”) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys’ fees and
expenses of litigation) (collectively, “Losses”) arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by BI in this Agreement, or any breach or
violation of any covenant or agreement of BI in or pursuant to this Agreement, (b) the negligence or willful misconduct by or of BI or any of its Related Parties, and their respective directors, officers, employees and agents, and (c) any
theory of product liability (including, but not limited to, actions in the form of tort, warranty or strict liability) arising out of or resulting from BI’s exercise of any rights 

  
 -24-

 
granted hereunder. Furthermore, BI shall have no obligation to indemnify the Regulus Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of,
or inaccuracy in, any representation or warranty made by Regulus in this Agreement, or any breach or violation of any covenant or agreement of Regulus in or pursuant to this Agreement, or the negligence or willful misconduct by or of any of the
Regulus Indemnitees. 
 10.6.2 Indemnification by Regulus. Regulus shall indemnify, hold harmless, and defend BI, its
Affiliates and their respective directors, officers, employees and agents (“BI Indemnitees”) from and against any and all Losses arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any
representation or warranty made by Regulus in this Agreement, or any breach or violation of any covenant or agreement of Regulus in or pursuant to this Agreement or (b) the negligence or willful misconduct by or of Regulus or any of its Related
Parties, and their respective directors, officers, employees and agents, and (c) any theory of product liability (including, but not limited to, actions in the form of tort, warranty or strict liability) arising out of or resulting from
Regulus’s exercise of any rights granted hereunder. Furthermore, Regulus shall have no obligation to indemnify the BI Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy
in, any representation or warranty made by BI in this Agreement, or any breach or violation of any covenant or agreement of BI in or pursuant to this Agreement, or the negligence or willful misconduct by or of any of the BI Indemnitees. 

10.6.3 Indemnification Procedure. In the event of any such claim against any BI Indemnitee or Regulus Indemnitee
(individually, an “Indemnitee”), the indemnified Party shall promptly notify the other Party in writing of the claim and the indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its
settlement. The Indemnitee shall cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action or proceeding. The indemnifying Party shall not be liable for any settlements, litigation costs or expenses
incurred by any Indemnitee without the indemnifying Party’s written authorization. Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in
Sections 10.6.1 or 10.6.2 may apply, the indemnifying Party shall promptly notify the Indemnitees, which may be represented in any such action or proceeding by separate counsel at their expense; provided, that the indemnifying
Party shall be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party. Any other provision of this Article 10 to the contrary notwithstanding, no
Indemnitee under this Agreement shall be required to waive a conflict of interest under any applicable rules of professional ethics or responsibility if such waiver would be required for a single law firm to defend both the indemnifying Party and
one or more Indemnitees. In such case, the indemnifying Party shall provide a defense of the affected Indemnitees through a separate law firm reasonably acceptable to the affected Indemnitees at the indemnifying Party’s expense. 

10.6.4 Insurance. Each Party shall maintain insurance with respect to its activities hereunder in commercially reasonable amounts.

  
 -25-

 Article 11 
 MISCELLANEOUS PROVISIONS 
 11.1 Governing Law. This Agreement shall be construed and
the respective rights of the Parties determined according to the substantive laws of the State of New York notwithstanding the provisions governing conflict of laws under such New York law to the contrary. 

11.2 Assignment. Except as provided in this Section 11.3, this Agreement may not be assigned or otherwise transferred, nor may any
right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party, such consent not to be unreasonably withheld. Either Party may, however, without the other Party’s consent, assign this Agreement
and its rights and obligations hereunder: (a) to an Affiliate; or (b) in connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreement relates to a Third Party, whether by merger,
sale of stock, sale of assets or otherwise, provided that in the event of such a sale or transfer (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse
triangular merger)), intellectual property rights of the acquiring party in such sale or transfer (if other than one of the Parties to this Agreement) shall not be included in the technology licensed hereunder or otherwise subject to this Agreement.
To the extent that the assigning Party survives as a legal entity, the assigning Party shall remain responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned to such assignee. 

11.3 Amendments. This Agreement and the Schedules referred to in this Agreement constitute the entire agreement between the Parties with respect
to the subject matter hereof, and supersede all previous arrangements with respect to the subject matter hereof, whether written or oral. Any amendment or modification to this Agreement shall be made in writing signed by both Parties. 

11.4 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties hereto to the
other shall be in writing and (a) delivered by hand, (b) sent by nationally recognized overnight delivery service, (c) sent by registered or certified mail, return receipt requested, postage prepaid, or (d) sent by facsimile
transmission confirmed by prepaid, registered or certified mail letter, and shall be deemed to have been properly served to the addressee upon receipt of such written communication, in any event to the following addresses: 

 

			
	 If to Regulus:
	  	Regulus Therapeutics Inc.
		
		  	3545 John Hopkins Ct., Suite 210
		
		  	San Diego, CA 92121
		
		  	Attention: CSO
		
		  	Fax: 858-202-6363

  
  
  

 

  
 -26-

			
	 With a copy to:
	  	
		
		  	Regulus Therapeutics Inc.
		
		  	3545 John Hopkins Ct., Suite 210
		
		  	San Diego, CA 92121
		
		  	Attention: Senior Director, Legal Affairs
		
		  	Fax: 858-202-6363
		
		  	
	 If to BI:
	  	Biogen Idec MA Inc.
		
		  	133 Boston Post Road
		
		  	Weston, MA 02493
		
		  	 Attention: Teresa Compton, Vice
 President Discovery Science

		
		  	Fax: 617-679-2625
		  	
	With a copy to:	  	
		
		  	Biogen Idec MA Inc.
		
		  	133 Boston Post Road
		
		  	Weston, MA 02493
		
		  	 ATTN: Executive Vice President,
 Chief Legal Officer

		
		  	Fax: 866-897-6623

 Either Party may change its address to which notices shall be sent by giving notice to the other Party in the manner
herein provided. 
 11.5 Force Majeure. No failure or omission by either Party in the performance of any obligation of this Agreement
shall be deemed a breach of this Agreement or create any liability if the same shall arise from any cause or causes beyond the control of such Party, including, but not limited to, the following: acts of god; acts or omissions of any government; any
rules, regulations or orders issued by any governmental authority or by any officer, department, agency or instrumentality thereof; fire; storm; flood; earthquake; accident; war; rebellion; insurrection; riot; and invasion; provided that such
Party provides notice to the other Party of such an event and such failure or omission resulting from one of the above causes is cured as soon as is practicable. 

  
 -27-

 11.6 Compliance with Applicable Laws. Neither Party shall export any technology licensed to it by the
other Party under this Agreement except in compliance with U.S. export laws and regulations. The Parties shall at all times comply with all laws and regulations applicable to its activities under this Agreement. 

11.7 Independent Contractors. It is understood and agreed that the relationship between the Parties is that of independent contractors and that
nothing in this Agreement shall be construed as authorization for either Regulus or BI to act as agent for the other. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the
Parties or any of their agents or employees for any purpose, including tax purposes, or to create any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall have any
express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

11.8 Further Assurances. Each Party hereto agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as
may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.9 No Strict Construction. This
Agreement has been prepared jointly and shall not be strictly construed against either Party. 
 11.10 Headings. The captions or headings
of the sections or other subdivisions hereof are inserted only as a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof. 
 11.11 No Implied Waivers; Rights Cumulative. No failure on the part of Regulus or BI to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided
by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any
single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege. 
 11.12 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid
provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would
have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable of one or several provisions of this Agreement shall not affect the validity of this Agreement as
a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or
unenforceable provisions. 

  
 -28-

 11.13 No Third Party Beneficiaries. No person or entity other than BI, Regulus and their respective
Affiliates and permitted assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 
 11.14 Execution in Counterparts. This Agreement may be executed in counterparts, including by facsimile or by electronic copies delivered by email, each of which counterparts, when so executed and
delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument. 
 Signature Page Follows 

  
 -29-

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above. 
  

			
	REGULUS THERAPEUTICS INC.
		
	By:	 	/s/ Kleanthis G. Xanthopoulos

 
			
	Name:	 	Kleanthis G. Xanthopoulos, Ph.D.

 
			
	Title:	 	President and CEO

  

			
	BIOGEN IDEC MA INC.
		
	By:	 	/s/ Steven H. Holtzman

 
			
	Name:	 	Steven H. Holtzman

 
			
	Title:	 	EVP Corporate Development

  
  
 Signature Page to Collaboration and License Agreement 

 Schedule A 
 Research Plan 
 Exhibit A 
 Executive Summary 
 Regulus Therapeutics is a biopharmaceutical company leading the
discovery and development of innovative new products based on microRNAs. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length that regulate gene expression. Nearly 700 microRNAs have been identified in the human genome, and
more than one-third of all human genes are believed to be regulated by microRNAs. As a single microRNA can regulate entire networks of genes, these new molecules are considered the master regulators of the genome. microRNA expression or function has
been shown to be significantly altered in many disease states, including immune-mediated diseases like multiple sclerosis (MS), and, as such, represent a brand new class of targets for therapeutic intervention and a novel set of molecular biomarkers
for diagnostic and prognostic tests. 
 Biogen is a world-wide leader in MS research and a leading provider of drugs used to treat and manage MS
disease. Avonex and Tysabri are marketed drugs for the treatment of MS disease and Biogen has several other late stage development programs including [...***...]. Biogen is committed to better understanding the disease pathology of MS and its
various disease forms so that patients can receive the most appropriate medicine. In the course of its clinical trials, Biogen has amassed a comprehensive collection of patient samples bringing tremendous value to translational medicine research.
This collaboration will bring together the technical capabilities of Regulus with biology expertise and well annotated sample collection of Biogen. Identification of reliable biomarkers for MS has the potential for improved diagnosis, enhanced
monitoring of disease activity and progression, and evaluation of treatment response. 
 microRNA Biomarker Discovery Plan: 

Overview: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the brain and spinal cord, primarily affecting young adults.
Many MS patients have a relapse remitting course (RRMS), which is unpredictable, and results in episodes of acute inflammation and neurological dysfunction. Gene expression analysis has been a useful tool to provide information about the molecular
pathways involved in MS pathogenesis, and studies have identified different expression patterns between relapses and remission. microRNAs have been shown to be regulators of immune biology and key players in the pathogenesis of neurological
diseases. [...***...]. 
 This collaborative work plan between Regulus and Biogen describes [...***...]. 

The primary goal of the discovery project is [...***...] 

  
 ***Confidential
Treatment Requested 

 [...***...]. 
 [...***...]. 
 Phased Approach: The discovery plan will be a multi-phased approach.

 The ‘prep phase’ will be comprised of [...***...]. Phase 1 will be [...***...]. Phase 2 is [...***...]. Phase 3
will [...***...]. 
 Regulus is currently evaluating [...***...]. [...***...]. 

Parallel to the technology evaluation, [...***...]. 
 During Phase 1, [...***...]. 
 During Phase 2, [...***...]. 

  
 ***Confidential
Treatment Requested 

 Phase 3 will be used to [...***...]. 
 Timetable of Activities: 
  

							
	
ACTIVITY
	 	DURATION (estimates)	  	TIMELINE
 (estimates)
	  	 
	 Prep phase.
[...***...]
	 	[...***...]	  	[...***...]	  	 
	 Phase 1.
[...***...]
	 	[...***...]	  	[...***...]	  	 
	 Phase 2.
[...***...]
	 	[...***...]	  	[...***...]	  	 
	 Phase 3.
[...***...]
	 	[...***...]	  	[...***...]	  	 

 Assumptions: 
 The above timetable assumes that the relevant human samples are available from Biogen. 

Research Program Staffing: 
 It is
envisioned that an initial team of [...***...] will be required to staff this effort. Below are brief descriptions of the proposed staffing requirements. 

	 	•	 	 [...***...] 

	 	•	 	 [...***...] 

	 	•	 	 [...***...] 

Discovery Plan Activities and Milestones: 
  

	 	•	 	 Prep Phase. [...***...] 

	 	o	Goal: [...***...] 

	 	o	Activities: 

	 	¡	[...***...] 

	 	¡	[...***...] 

	 	¡	[...***...] 

  
 ***Confidential
Treatment Requested 

	 	o	Outcome: [...***...] 

	 	o	Criteria: [...***...]. 

	 	o	Risk assessment: [...***...] 

  

	 	•	 	 Phase 1. [...***...] 

	 	o	Goal: [...***...] 

	 	¡	Experiment: [...***...] 

	 	¡	Source of samples: [...***...] 

	 	¡	microRNA Extraction, Quality Control and Analysis: [...***...] 

	 	¡	Type of assays: [...***...] 

	 	¡	Bioinformatics: [...***...] 

	 	o	Criteria for success: [...***...] 

	 	o	Risk assessment: [...***...]. 

  

	 	•	 	 Phase 2. [...***...] 

	 	o	Goal: [...***...]. 

	 	¡	Experiment: [...***...] 

	 	¡	Source of samples: [...***...] 

	 	¡	microRNA Extraction Quality Control and Analysis: [...***...] 

	 	¡	Type of assays: [...***...] 

	 	¡	Bioinformatics: [...***...] 

	 	o	Criteria for success: [...***...] 

	 	o	Risk assessment: [...***...] 

  

	 	•	 	 Phase 3. [...***...]

	 	o	Goal: [...***...] 

	 	¡	Experiment: [...***...] 

	 	¡	Source of samples: [...***...] 

	 	¡	microRNA Extraction Quality Control and Analysis: [...***...] 

	 	¡	Type of assays: [...***...] 

	 	¡	Bioinformatics: [...***...] 

	 	o	Criteria for success: [...***...]. 

  
 ***Confidential
Treatment Requested 

	 	o	Risk assessment: [...***...] 

Summary: Regulus, the leading company in microRNA technology, has developed a microRNA biomarker workflow and is proposing to work with Biogen as
a [...***...] in the discovery and development of microRNA biomarkers for MS and potentially broader disease indications. 

  
 ***Confidential
Treatment Requested 

 Schedule B 
 Phase 1 of Research
  

	 	1.	[...***...] 

	 	2.	[...***...] 

 Phase 2 of
Research
  

	 	1.	[...***...] 

	 	2.	[...***...] 

 Phase 3 of
Research
  

	 	1.	[...***...] 

  
 ***Confidential
Treatment Requested 

 Schedule C 
 [...***...] Agreement dated [...***...] and [...***...] 
 Agreement dated
[...***...] 
 [...***...] Agreement dated [...***...] 
 [...***...] Agreement [...***...] 

  
 ***Confidential
Treatment Requested 

 EXHIBIT I

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]